American College of Clinical Pharmacy
      Search      Cart
         

Continuing Pharmacy Education (CPE) Credit

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE). The 2019 ACCP Annual Meeting will provide up a maximum of 22.75 contact hours of CPE credit. To receive CPE for Annual Meeting sessions, each attendee must claim the relevant CPE hours at www.accp.com/ce within 60 days of the session. Statements of credit will be available at CPE Monitor within 2–3 business days.

To receive BCACP, BCCCP, BCGP, BCOP, or BCPS recertification credit for a recertification related program offered at the 2019 ACCP Annual Meeting, each attendee must pay a $50 recertification posttest fee and submit a passing score on the posttest by the deadline listed in the session materials. The posttest will be made available on the “My Account” page of the ACCP website on the published date in the session materials.

Target Audience
The ACCP Annual Meeting is designed for clinical practitioners, educators, residents, fellows, and pharmacy students engaged in all aspects of clinical pharmacy.

Program Goals
The educational program developed for the 2019 ACCP Annual Meeting will provide attendees with new, high-quality information that is both challenging and applicable to their practice. Program goals are to

  • Update clinical pharmacists on new therapeutic advances and management strategies;
  • Enhance attendees’ clinical, research, teaching, and leadership skills;
  • Discuss the challenges of expanding the scope of pharmacy practice and emerging practice models; and
  • Present opportunities in clinical pharmacy and global health.

Guidance on the Guidelines: Recent Therapeutic Updates
October 26, 2019 9:45 AM

Activity No. 0217-0000-19-155-L01-P; 1.50 contact hours.
Application Based Activity

  • Moderator: Emily K. McCoy, Pharm.D., BCACP
    Associate Clinical Professor, Auburn University Harrison School of Pharmacy, Mobile, Alabama

Tip of the CAP: Managing Community-Acquired Pneumonia in 2019
  • Speaker: Emily L. Heil, Pharm.D., BCPS-AQ ID
    Associate Professor, University of Maryland School of Pharmacy, Baltimore, Maryland
Learning Objectives
1. Identify key changes in the management of community-acquired pneumonia (CAP) following publication of recent guidelines.
2. Discuss the role of corticosteroids in the management of moderate and severe CAP.
3. Determine appropriate empiric therapy for patients presenting with CAP based on patient- and institution-specific factors.

Time is Brain: Updates in Stroke Management
  • Speaker: Karen Berger, Pharm.D., BCPS, BCCCP
    Neurocritical Care Clinical Pharmacist, New York Presbyterian Hospital - Weill Cornell Medical Center, New York, New York
Learning Objectives
1. Identify key changes and controversies in the management of ischemic stroke following publication of recent guidelines.
2. Evaluate the potential place in therapy of tenecteplase in the management of ischemic stroke.
3. Discuss the pharmacist’s role in post-stroke care.

Don’t Go Breakin’ My Heart: Updates, Controversies, and Clinical Considerations in Heart Failure Management
  • Speaker: Robert J. DiDomenico, Jr., Pharm.D., FCCP, FACC, FHFSA, BCPS-AQ Cardiology
    Associate Professor, University of Illinois at Chicago, Chicago, Illinois
Learning Objectives
1. Identify key changes in the management of heart failure following publication of recent guidelines.
2. Evaluate risks versus benefits of cessation of medical therapy in patients with heart failure with recovered ejection fraction.
3. Discuss management considerations for patients with heart failure with preserved ejection fraction and heart failure with mid-range ejection fraction.
4. Discuss the pharmacist’s role after hospital discharge for a patient with heart failure.

Question and Answer

Big Plans for Big Data: Applications for the Practicing Clinician
October 26, 2019 9:45 AM

Activity No. 0217-0000-19-242-L04-P; 1.50 contact hours.
Knowledge Based Activity

  • Moderator: James N. Fleming, PharmD, FCCP
    Clinical Pharmacy Specialist, Solid Organ Transplant at the Medical University of South Carolina, Medical University of South Carolina, Charleston, South Carolina

Big Data in Healthcare: Opportunities & Challenges
  • Speaker: Michael R. Gionfriddo, Pharm.D., Ph.D.
    Assistant Professor, Geisinger's Center for Pharmacy Innovation and Outcomes, Forty Fort, Pennsylvania
Learning Objectives
1. Define Big Data and describe its relevance to the healthcare industry.
2. Describe the sources of Big Data and its generalizability to local populations.
3. Discuss techniques for performing predictive analytics and the role of Big Data.
4. Describe challenges associated with Big Data management.

Big Data at the Bedside: Uses for Improving Care and Reducing Costs
  • Speaker: Erik E. Abel, Pharm.D., MBA, BCPS
    Director of Clinical Transformation, Finance & Clinical Operations, Clinical Transformation Office, Highmark Health, Pittsburgh, Pennsylvania
Learning Objectives
1. Describe how a practicing clinician can use Big Data at the bedside to make patient-specific treatment decisions.
2. Describe how to apply Big Data in preventative medicine and predictive models.
3. Explain how Big Data can be used to leverage drug cost and utilization data to reduce pharmacy expenditures.
4. Apply Big Data principles to a clinical pharmacy scenario to demonstrate its utility in improved patient care and/or reduced costs.

Pharmacogenomic Testing: Opportunities and Best Practices for Pharmacists
October 26, 2019 9:45 AM

Activity No. 0217-0000-19-157-L04-P; 1.50 contact hours.
Knowledge Based Activity

  • Moderator: Christine M. Walko, Pharm.D., BCOP, FCCP
    Associate Member, Department of Individualized Cancer Management, Moffitt Cancer Center, Tampa, Florida

Pharmacogenomics in Mental health: Developing an Evidence-based Practice
  • Speaker: Teresa T. Ho, Pharm.D., BCPS
    Assistant Professor, Department of Pharmacy Practice; Assistant Professor, College of Medicine Internal Medicine, University of South Florida, Tampa, Florida
Learning Objectives
1. Review the most clinically relevant gene-drug pairs the influence psychiatric medication dosing.
2. Describe the challenges of translating pharmacogenomic testing into psychiatric drug therapy management, including test ordering, insurance billing, documentation of results and patient education.
3. Identify available resources and guidelines to design best practices for translation into clinical practice.

Integrating Pharmacogenomics into Comprehensive Medication Management
  • Speaker: James Kevin Hicks, Pharm.D., Ph.D.
    Personalized Medicine Specialist, Moffitt Cancer Center, Tampa, Florida
Learning Objectives
1. Review clinically relevant genes commonly included on pharmacogenomic testing panels.
2. Identify primary literature and clinical guidelines to inform practice recommendations and medical therapy management decisions.
3. Apply evidence-based medicine to pharmacogenomic-guided therapy in a case-based patient scenario.

The Role of the Pharmacist in the 23andMe Testing Era
  • Speaker: Henry Dunnenberger, IV, Pharm.D.
    Director - Pharmacogenomics, NorthShore University HealthSystem, Evanston, Illinois
Learning Objectives
1. Describe the types of genetic information being provided through large panel, direct to consumer genetic testing.
2. Identify potential opportunities for pharmacy to enhance the clinical value of the information provided in these tests when approached.
3. Formulate recommendations for counseling content and identify additional resources appropriate for patients looking for understanding of their test results.

Diversity in Pharmacy Leadership: Breaking the Glass Ceiling
October 26, 2019 9:45 AM

Activity No. 0217-0000-19-154-L04-P; 1.50 contact hours.
Application Based Activity

  • Moderator: Linda M. Sobeski, Pharm.D., BCPS
    Clinical Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska

Disparities in Pharmacy Leadership: Fact or Fiction?
  • Speaker: Janet P. Engle, Pharm.D., Ph.D. (Hon), FCCP, FAPhA, FNAP
    Executive Director, Accreditation Council for Pharmacy Education Chicago, Illinois
Learning Objectives
1. Review the history of gender and minority disparities in pharmacy leadership.
2. Evaluate the current data surrounding gender and minority disparities in pharmacy leadership.
3. Assess the potential outcomes of diversity in pharmacy leadership.

Diversity in Pharmacy Leadership: Biases and Barriers
  • Speaker: Marie A. Chisholm-Burns, Pharm.D., MPH, MBA, FCCP, FASHP, FAST
    Dean, College of Pharmacy, University of Tennessee, Memphis, Tennessee
Learning Objectives
1. Identify the impact of conscious and unconscious bias on diversity in leadership.
2. Assess the impact of work-life integration on diversity in leadership.
3. Evaluate the impact of mentorship and institutional support on diversity in leadership.

Diversity in Pharmacy Leadership: Roadmap to Success
  • Speaker: Hope E. Campbell, Pharm.D., BCPS
    Associate Professor, Pharmacy Practice, Belmont University College of Pharmacy, Nashville, Tennessee
Learning Objectives
1. Examine opportunities for advancing diversity in pharmacy leadership.
2. Discuss strategies for addressing biases and barriers to diversity in pharmacy leadership.
3. Identify key elements for cultivation of diversity in pharmacy leadership.

Navigating Regulatory and Payment Barriers to Medication Optimization: Advocating for Business Models that Sustain Clinical Practice
October 26, 2019 9:45 AM

Activity No. 0217-0000-19-156-L03-P; 2.00 contact hours.
Knowledge Based Activity

  • Moderator: Kathy Pham, Pharm.D.
  • Facilitator: John K. McGlew, M.A.
    Director, Government Affairs, American College of Clinical Pharmacy (ACCP), Washington, D.C.

Getting the Definitions Right
  • Speaker: Curtis E. Haas, Pharm.D., FCCP, BCPS
    Director of Pharmacy, University of Rochester Medical Center, Rochester, New York
Learning Objectives
Summarize the differences between collaborative practice agreements, standing orders, statewide protocols, and related terms.
Compare the application of these terms as mechanisms to expand clinical pharmacists’ scope of practice.
Identify key components of collaborative practice agreements that allow clinical pharmacists to effectively contribute to medication optimization

Making the Business Case: CMM in Value Based Payment and Delivery
  • Speaker: Jon Easter, B.S.Pharm.
    Director, Center for Medication Optimization; UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina
Learning Objectives
Describe the multimodal approach to advancing practice through policy change related to medication optimization across key payers and practice settings.
Describe how health policy decisions can incentivize new payment models and scale care delivery innovations that will improve patient outcomes and lower the total cost of care.
Discuss key concepts to supporting medication optimization in value-based care delivery and payment models
Summarize the importance of clinical practice and advocacy efforts to the advancement of clinical pharmacists’ contribution to achieving medication optimization.

Congressional and Legislative Advocacy
  • Speaker: Paul T. Kelly
    President, Capitol Advocacy and Government Affairs, LLC, Washington, D.C.
Learning Objectives
Describe the policy principles of ACCP’s Medicare Initiative to establish formal, statutory coverage for comprehensive medication management (CMM) services within the Medicare program beyond recognition as providers.
Describe why a comprehensive approach to policy change, including payment reform that formally integrates clinical pharmacists to achieve medication optimization, is essential in order to meaningfully address the needs of our health care system.
Describe how federal laws and regulations – including the Affordable Care Act (ACA) and the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) – can help support medication optimization in comprehensive medication management practices by advancing team-based patient-centered structures.
Identify key strategies for successful advocacy at the state and federal level that can enhance clinical pharmacists’ involvement in medication optimization beyond provider status recognition.

Panel Discussion
  • Moderator: Kathy Pham, Pharm.D.
  • Speaker: Curtis E. Haas, Pharm.D., FCCP, BCPS
    Director of Pharmacy, University of Rochester Medical Center, Rochester, New York
  • Speaker: Jon Easter, B.S.Pharm.
    Director, Center for Medication Optimization; UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina
  • Speaker: Paul T. Kelly
    President, Capitol Advocacy and Government Affairs, LLC, Washington, D.C.

Scientific Poster Session, I: Heart-Failure Poster CPE
October 26, 2019 11:30 AM

Activity No. 0217-0000-19-207-L01-P; 0.50 contact hours.
Knowledge Based Activity

    Learning Objectives
    1. Discuss current research findings on heart failure.
    2. Identify four studies related to heart failure important to clinical pharmacy.

    Sat-22 Influence of Sodium-Containing Antibiotics for Bacterial Infections on Morbidity in Patients with Heart Failure

    Sat-23 Potentially Harmful Medication Use among Medication Therapy Management patients with Congestive Heart Failure

    Sat-19 Specialty review improves heart failure care among co-managed and primary care managed patients at VA Portland Health Care System

    Sat-21 Evaluating discharge diuretic regimens and all-cause thirty-day readmission rates in heart failure exacerbation

    Sat-16 Evaluation of Hyperkalemia Risk in Heart Failure Patients on Spironolactone with Estimated Glomerular Filtration Rate < 30 mL/min

    Scientific Poster Session, I: Vancomycin/Infectious Disease Poster CPE
    October 26, 2019 12:00 PM

    Activity No. 0217-0000-19-208-L01-P; 0.50 contact hours.
    Knowledge Based Activity

      Learning Objectives
      1. Describe recent findings of research relevant to the clinical use of vancomycin in infectious disease pharmacy practice.
      2. Review four research studies involving the use of vancomycin important to clinical pharmacy.

      Sat-34 Utility of NephroCheck® in Predicting Acute Kidney Injury (AKI) Among Sepsis Patients with Vancomycin and Beta-Lactam Exposure

      Sat-77 Pharmacokinetic-pharmacodynamic target attainment of cefilavancin and vancomycin: a Monte Carlo analysis

      Sat-98 Vancomycin versus linezolid for the treatment of acute pulmonary exacerbations of cystic fibrosis

      Sat-74 Vancomycin AUC/MIC and treatment outcomes in MRSA bacteremia

      Sat-123 Association Between Vancomycin Area Under the Curve and Clinical Outcomes among Patients With Serious Methicillin-Resistant Staphylococcus aureus Bacteremia

      Author Development Series, Part 1
      October 26, 2019 1:00 PM

      Activity No. 0217-0000-19-236-L04-P; 1.50 contact hours.
      Knowledge Based Activity

      • Moderator: Alan J. Zillich, Pharm.D., FCCP
        William S. Bucke Professor and Head, Department of Pharmacy Practice, Purdue University College of Pharmacy, Indianapolis, Indiana

      Habits of a Productive Scientific Writer
      • Speaker: Alan J. Zillich, Pharm.D., FCCP
        William S. Bucke Professor and Head, Department of Pharmacy Practice, Purdue University College of Pharmacy, Indianapolis, Indiana
      Learning Objectives
      1. Define strategies to overcome writing challenges
      2. Develop personal writing goals
      3. Discuss methods to improve your scholarly output

      Writing Effective Manuscript Titles and Abstracts
      • Speaker: C. Lindsay DeVane, Pharm.D., FCCP, BCPP
        Editor-in-Chief, Pharmacotherapy Professor Emeritus, Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston, South Carolina
      Learning Objectives
      1. Describe the basic elements of an effective manuscript title.
      2. Describe the content to include in each section of a structured abstract.
      3. Demonstrate an ability to identify the characteristics of an effective manuscript title and abstract.

      Establishing Outcomes (Teaching and Learning Primer)
      October 26, 2019 1:45 PM

      Activity No. 0217-0000-19-209-L04-P; 4.00 contact hours.
      Application Based Activity

      • Speaker: Daniel S. Longyhore, Pharm.D., M.S., BCACP
        System Director for Knowledge Management Geisinger, Enterprise Pharmacy, Wilkes Barre, Pennsylvania
      • Speaker: Pamela L. Stamm, Pharm.D., FASHP, BCPS, BCACP, CDE
        Associate Professor of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, Auburn, Alabama
      • Speaker: Angela L. Bingham, Pharm.D., BCPS, BCNSP, BCCCP
        Associate Professor of Clinical Pharmacy, University of the Sciences – Philadelphia College of Pharmacy; Critical Care/Nutrition Support Clinical Pharmacy Specialist, PGY2 Critical Care Residency Program Director, Cooper University Hospital, Camden, New Jersey,
      Learning Objectives
      1. Create clearly defined ability-based outcomes for learning.
      2. Develop course/rotation-level, assessment-level, & activity-level outcomes and objectives.
      3. Create an upstream and downstream alignment between outcomes and objectives.
      4. Define the objectives a learning experience must provide the opportunity to demonstrate.
      Research Primer
      October 26, 2019 1:45 PM

      Activity No. 0217-0000-18-227-L04-P; 4.00 contact hours.
      Application Based Activity

      • Speaker: Jeremy Thomas, Pharm.D.
        Associate Professor, Department of Pharmacy, University of Arkansas for Medical Sciences, College of Pharmacy, Little Rock, Arkansas
      • Speaker: Sandra L. Kane-Gill, Pharm.D., M.Sc., FCCP, FCCM
        Professor of Pharmacy and Therapeutics, University of Pittsburgh, School of Pharmacy, Pittsburgh, Pennsylvania
      • Speaker: Gary L. Cochran, Pharm.D., S.M.
        Associate Professor of Pharmacy Practice, University of Nebraska Medical Center, College of Pharmacy, Omaha, Nebraska
      • Speaker: Jacqueline McLaughlin, Ph.D., M.S.
        Assistant Professor, Educational Innovation and Research; Director, Office of Strategic Planning and Assessment, University of North Carolina Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
      Learning Objectives
      1. Describe the steps in developing a study protocol for the research project.
      2. Practice the iterative process of creating a defined and focused research question using PICO and FINER criteria.
      3. Utilize publications to identify research questions, study designs, and methodologies.
      4. Identify resources needed to conduct the research project and answer the research question.
      5. Understand the ethical considerations and IRB processes within each research strategy.
      6. Describe “best practices” for establishing and maintaining optimal relationships with your research mentor.
      Leadership Primer, I
      October 26, 2019 1:45 PM

      Activity No. 0217-0000-19-243-L04-P; 4.00 contact hours.
      Application Based Activity

      • Speaker: Robert S. Beardsley, Ph.D.
        Professor and Vice Chair for Administration, Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, Maryland
      • Speaker: Peter Hurd, Ph.D.
        Professor and Department Chair, Pharmaceutical and Administrative Sciences, St. Louis College of Pharmacy, St. Louis, Missouri
      • Speaker: Robert E. Smith, Pharm.D.
        Professor Emeritus, Harrison School of Pharmacy, Auburn University, Auburn, Alabama
      Learning Objectives
      1. Describe the importance of taking personal responsibility for self-leadership in developing leadership capabilities.
      2. Describe ways that you can be proactive when working with others in various settings, such as performance evaluation.
      3. Produce the start of a personal mission statement, applying to both personal and work-related areas of your life.
      4. Apply time management strategies, based on your mission statements, to your personal and professional leadership challenges.
      5. Evaluate the use of principle-centered power in the pharmacy environment.
      6. Define leadership in terms used by various individuals.
      7. Describe the various attributes of leadership.
      8. Apply Blake and Mouton’s work to leadership at various practice settings.
      9. Describe motivation based on the work of Maslow.
      10. Differentiate between motivators and hygiene factors as defined by Herzberg.
      11. Describe the various components of the Transtheoretical Model as they relate to pharmacy leadership.
      12. Apply the principles within the Transtheoretical Model to various practice settings.
      13. Discuss the need for change in pharmacy practice environments.
      Critical Care PRN Focus Session -- Anticoagulation Controversies in the ICU
      October 26, 2019 1:45 PM

      Activity No. 0217-0000-19-173-L01-P; 1.50 contact hours.
      Application Based Activity

      • Moderator: Komal Pandya, Pharm.D., BCCCP
        Acute Care Pharmacy Services. Critical Care Pharmacist - Cardiothoracic Surgery; Assistant Adjunct Professor, UK College of Pharmacy Lexington, Kentucky

      Are DOACs Novel Enough to Treat HIT?
      • Speaker: Kevin R. Donahue, Pharm.D., BCPS
        Clinical Pharmacy Specialist: Cardiac Critical Care Houston Methodist Hospital, Houston, Texas
      Learning Objectives
      1. Summarize evidence for use of DOACs for patients with confirmed HIT.
      2. Identify critically ill patients appropriate for treatment of HIT with a DOAC.
      3. Given a patient-specific scenario, design an appropriate DOAC regimen.

      Avoiding Clots in a Crisis-Balancing Anticoagulation in ECMO
      • Speaker: Jonathan A. Bain, Pharm.D, BCCCP, BCPS
        Lead Pharmacist and Owner, Rx Compound Centre, Columbia, Tennessee
      Learning Objectives
      1. Evaluate the utility of using coagulation assays for monitoring patients on ECMO.
      2. Define the optimal anticoagulation goal for patients on ECMO.
      3. Discuss the risks and benefits of different anticoagulation options in patients undergoing ECMO.

      To Lyse or Not to Lyse: Thrombolytic Strategies in Acute Pulmonary Embolism
      • Speaker: Tyree H. Kiser, Pharm.D., FCCP, BCPS
        Professor, University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy & Pharmaceutical Sciences, Aurora, Colorado
      Learning Objectives
      1. Evaluate the evidence for use of thrombolytic therapy in patients with intermediate-risk pulmonary embolism.
      2. Select and recommend an appropriate dosing strategy for thrombolytic use in patients with pulmonary embolism.

      Infectious Diseases PRN and Society of Infectious Diseases Pharmacists Focus Session -- Power Gaps in Stewardship: Decision Making for Diagnostics and Transitions of Care
      October 26, 2019 1:45 PM

      Activity No. 0217-0000-19-186-L01-P; 1.50 contact hours.
      Knowledge Based Activity

      • Moderator: Whitney J. Nesbitt, Pharm.D.
        Antimicrobial Stewardship Clinical Specialist, Vanderbilt University Medical Center, Nashville, Tennessee

      The Fundamentals of Outpatient Parenteral Antimicrobial Therapy: Who, What, When, Why, and How.
      • Speaker: John A. Bosso, Pharm.D., FCCP, FIDP
        Professor Emeritus of Clinical Pharmacy and Medicine, Colleges of Pharmacy and Medicine, Medical University of South Carolina,Charleston, South Carolina
      Learning Objectives
      1. Review the 2018 Infectious Diseases Society of America updated clinical guideline on the management of outpatient parenteral antimicrobial therapy.
      2. Describe common clinical syndromes and complications managed in OPAT centers and highlight best practice antimicrobial stewardship recommendations.
      3. Discuss effective metrics/tools to evaluate the quality of OPAT care.

      The 'Route' to Success: Evaluating the Role of Oral Antibiotics for Complicated Infections
      • Speaker: Nick Mercuro, Pharm.D.
        Pharmacy Specialist, Infectious Diseases, Department of Pharmacy Services, Beth Israel Deaconess Medical Center, Boston, Massachusetts
      Learning Objectives
      1. Describe the pharmacokinetic properties of antibiotics that would be ideal for oral therapy.
      2. Evaluate the current literature related to the use of oral antibiotics for complicated infections.
      3. Identify appropriate patients who are candidates for oral antibiotic therapy for complicated infections.

      Demonstrate Integration of Diagnostic Stewardship into Daily Practice.
      • Speaker: Stephanie Harding, Pharm.D., BCPS-AQ ID
        Infectious Diseases Clinical Pharmacist, Wesley Healthcare, Wichita, Kansas
      Learning Objectives
      1. Explain diagnostic stewardship and its role in antimicrobial stewardship programs (ASP).
      2. Describe laboratory, provider and ASP strategies to avoid inappropriate testing.
      3. Discuss how diagnostic stewardship results can improve patient care and safety.

      Nephrology PRN Focus Session -- Comprehensive Medication Management Across the Continuum of Care in Patients with ESRD
      October 26, 2019 1:45 PM

      Activity No. 0217-0000-19-174-L01-P; 1.50 contact hours.
      Knowledge Based Activity

      • Moderator: Estella M. Davis, Pharm.D., BCPS
        Associate Professor, Creighton University School of Pharmacy and Health Professions, Omaha, Nebraska

      Pharmacy Strategies to Improve Transitions of Care in Patients with End Stage Renal Disease
      • Speaker: Wendy L. St. Peter, Pharm.D., FCCP, BCPS
        Professor, University of Minnesota, Minneapolis, Minnesota
      Learning Objectives
      1. Describe the unique risks and challenges that exist with transitions of care for patients with end stage renal disease (ESRD.
      2. Summarize current literature describing comprehensive medication therapy management programs in patients with ESRD.
      3. Discuss pharmacist led solutions to improve transitions of care in patients with ESRD.

      Medication Reconciliation: A New Quality Measure for Patients Receiving Care at Dialysis Facilities
      • Speaker: Harold J. Manley, Pharm.D., FCCP, FASN
        Senior Pharmacy Director, Dialysis Clinic, Albany, New York
      Learning Objectives
      1. Discuss the development of the new quality measure of medication reconciliation for patients receiving care at dialysis facilities.
      2. Review performance measure specifications for the new quality measure and compare them to currently endorsed medication reconciliation measures.
      3. Describe the role and impact of clinical pharmacists on the measure to improve quality of care for patients with ESRD.

      Author Development Series, Part 2
      October 26, 2019 2:30 PM

      Activity No. 0217-0000-19-237-L04-P; 2.00 contact hours.
      Knowledge Based Activity

      • Moderator: Stuart T. Haines, Pharm.D., BCPS, BCACP, BC-ADM
        Professor and Director, Division of Pharmacy Professional Development, University of Mississippi School of Pharmacy, Jackson, Mississippi

      Responding to Peer Review Comments: Do’s and Don’ts
      • Speaker: Stuart T. Haines, Pharm.D., BCPS, BCACP, BC-ADM
        Professor and Director, Division of Pharmacy Professional Development, University of Mississippi School of Pharmacy, Jackson, Mississippi
      Learning Objectives
      1. Recognize peer review comments that should and should not prompt manuscript revisions.
      2. Respond to a peer review comments by creating an author response report that is logically organized, specific, and positively worded.
      3. Determine when one should contact the journal editor(s).

      Suggested Guidelines for Retrospective Chart Reviews
      • Speaker: Jerry L. Bauman, Pharm.D., FCCP, FACC
        Dean Emeritus and Distinguished Professor Emeritus, University of Illinois at Chicago College of Pharmacy, Chicago, Illinois
      Learning Objectives
      1. Recount the advantages and shortcomings of retrospective cohort studies using patients' medical records
      2. List both mandatory and suggested elements for publication (in JACCP and Pharamacotherapy) of a retrospective cohort study using patients' medical records.
      3. List the key elements/checklist necessary for publishing a retrospective cohort study using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines as a suitable alternative to JACCP guidelines.

      Social Media for Scholars: Growing Your Impact Effectively and Efficiently
      • Speaker: Brent N. Reed, Pharm.D., FAHA, BCPS-AQ Cardiology
        Associate Professor, University of Maryland School of Pharmacy; Clinical Pharmacy Specialist, University of Maryland Medical Center, Baltimore, Maryland
      Learning Objectives
      1. List advantages and disadvantages of using social media to enhance one’s scholarly efforts.
      2. Outline a strategy for using social media to effectively grow one’s scholarship impact.
      3. Apply at least one method for using social media efficiently.

      Emergency Medicine PRN Focus Session -- Nothing Ventured, Nothing Gained: Established and Evolving Roles for Emergency Medicine Pharmacists
      October 26, 2019 3:30 PM

      Activity No. 0217-0000-19-187-L04-P; 1.50 contact hours.
      Application Based Activity

        Ready, Set, Start! Implementing Emergency Medicine Pharmacist Services from the Ground Up
        • Speaker: Jennifer Splawski, Pharm.D., BCPS
          Emergency Medicine Clinical Pharmacy Specialist, Pharmacy Services Clinical Coordinator - Loyola Medicine – MacNeal Hospital, Berwyn, Illinois
        Learning Objectives
        1. Appraise available literature supporting EM pharmacist services in the emergency department (ED) setting.
        2. Execute a plan to establish new EM pharmacist services in the ED setting.

        Sustain to Maintain? Not in my ED! Strategies to Justify and Expand Established Emergency Medicine Pharmacy Services
        • Speaker: Abby Bailey, Pharm.D., BCPS, BCCCP
          Emergency Medicine Pharmacy Specialist, University of Kentucky Chandler Medical Center, Lexington, Kentucky
        Learning Objectives
        1. Justify established EM pharmacist services to senior leadership within the health-care organization.
        2. Design strategies to expand opportunities in teaching, research, administration, and extender services.

        Hocus POCUS and Other Fun Tricks: Novel Practices and Roles at the Bedside for Emergency Medicine Pharmacists
        • Speaker: Nicole M. Acquisto, Nicole M. Acquisto, Pharm.D., FCCP, BCCCP
          Emergency Medicine Clinical Pharmacy Specialist, Department of Pharmacy Associate Professor, Department of Emergency Medicine, University of Rochester Medical Center, Strong Memorial Hospital, Rochester, New York
        Learning Objectives
        1. Identify novel services and roles for EM pharmacists that differ from traditional patient care activities at the bedside.
        2. Construct a plan to implement a novel service for EM pharmacists in the health care system and obtain buy-in from providers and nursing staff.

        Endocrine and Metabolism PRN Focus Session -- Into the Wild: Navigating the Jungles of Vascular Outcomes, Mountains of Adiposity, and Zebras of Diabetes
        October 26, 2019 3:30 PM

        Activity No. 0217-0000-19-175-L01-P; 1.50 contact hours.
        Application Based Activity

        • Moderator: Diana Isaacs, PharmD, BCPS, BCACP
          Clinical Pharmacy Specialist, Endocrinology & Metabolism Institute, Diabetes Center, Cleveland Clinic, Cleveland, Ohio

        Navigating the Jungles of Vascular Outcomes
        • Speaker: Dave L. Dixon, Pharm.D., BCPS, FCCP
          Associate Professor, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia
        Learning Objectives
        1. Compare and contrast varying characteristics and vascular outcomes of clinical trials with diabetes agents.
        2. Apply vascular outcome literature findings to patient case scenarios in diabetes management.

        Climbing the Mountains of Adiposity to Achieve Optimal Outcomes in Obesity
        • Speaker: Brian K. Irons, Pharm.D., FCCP, BCACP
          Professor of Pharmacy Practice Texas Tech University Health Sciences Center Lubbock, Texas
        Learning Objectives
        1. Interpret new literature of surgical and non-surgical options to treat obesity.
        2. Recommend the best treatment plan for patient case scenarios in obesity.

        Treating the Zebras of Diabetes
        • Speaker: Jennifer M. Trujillo, Pharm.D., BCPS, CDE
          Professor, University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado
        Learning Objectives
        1. Identify the less common forms of diabetes and the pathophysiology behind them.
        2. Explain the differences in treatment strategies of the less common forms of diabetes.

        Immunology/Transplant PRN Focus Session -- Path of Least Resistance: Narrowing and Minimizing Anti-Infectives in Solid Organ Transplantation
        October 26, 2019 3:30 PM

        Activity No. 0217-0000-19-176-L01-P; 1.50 contact hours.
        Knowledge Based Activity

        • Moderator: Aileen Chi, Pharm.D.

        Management of the Post-operative Cardiothoracic Transplant Recipient with Existing Infections Prior to Transplant
        • Speaker: Tamara E. Claridge, Pharm.D., BCPS
          Clinical Pharmacy Specialist Lung Transplant, Hospital of the University of Pennsylvania, Philadelphia, PA
        Learning Objectives
        1. Describe the prevalence of ventricular assist device infections and risk factors for persistence of these infections after orthotopic heart transplantation.
        2. Discuss the prevalence and risk factors for a recurrent infection post-lung transplant in patients with pre-existing native lung infections or colonization.
        3. Evaluate the appropriate choice and duration of surgical infection prophylaxis in cardiothoracic patients with pre-existing infections prior to transplant.
        4. Apply antimicrobial stewardship strategies to optimize antimicrobial use in cardiothoracic recipients with preexisting infections prior to transplant.

        Asymptomatic Bacteriuria in Solid Organ Transplant Recipients
        • Speaker: Lyndsey J. Bowman, Pharm.D.
          Kidney and Pancreas Transplant Pharmacotherapy Specialist; Co-Residency Program Director, PGY2 Solid Organ Transplant Resident Program; Clinical Coordinator, Solid Organ Transplant Pharmacists; Tampa General Hospital, Tampa, Florida
        Learning Objectives
        1. Discuss the prevalence and risk factors of asymptomatic bacteriuria in post-kidney transplant recipients.
        2. Review the risks of overtreatment of asymptomatic bacteriuria and development of antimicrobial resistance post-transplant.
        3. Evaluate management of asymptomatic bacteriuria post-transplant in solid organ transplant recipients.
        4. Discuss the role of antimicrobial stewardship in management of asymptomatic bacteriuria post-transplant.

        Antifungal Stewardship in Solid Organ Transplant
        • Speaker: Jason C. Gallagher, Pharm.D., FCCP, BCPS
          Clinical Professor, Temple University School of Pharmacy, Philadelphia, Pennsylvania
        Learning Objectives
        1. Discuss the risks and prevalence of fungal infections in the solid organ transplant population.
        2. Describe how fungal infections affect transplant outcomes.
        3. Review current antifungal therapies and mechanisms of fungal resistance.
        4. Evaluate the need for antifungal stewardship and illustrate implications of an antifungal stewardship program.

        New Investigator Award/Lecture— Cardiovascular Pharmacogenomics to Predict Adverse Drug Reactions: Heparin-Induced Thrombocytopenia and Beyond
        October 27, 2019 8:25 AM

        Activity No. 0217-0000-19-225-L01-P; 0.25 contact hours.
        Knowledge Based Activity

        • Award Winner: Jason H. Karnes, Pharm.D., Ph.D., BCPS
          Assistant Professor, University of Arizona, Tucson, Arizona
        Learning Objectives
        1. Review the current landscape of cardiovascular pharmacogenomics research.
        2. Discuss genetic predictors of heparin-induced thrombocytopenia and contributions of Dr. Jason Karnes’ research program to this body of literature.
        3. Discuss the prediction of diseases and adverse drug reactions using human leukocyte antigen alleles.
        Therapeutic Frontiers Lecture— Reducing Disability after Stroke: New Avenues
        October 27, 2019 10:25 AM

        Activity No. 0217-0000-19-226-L01-P; 0.50 contact hours.
        Knowledge Based Activity

        • Speaker: Susan C. Fagan, Pharm.D., FCCP, BCPS
          Jowdy Professor, Associate Head, Assistant Dean, University of Georgia College of Pharmacy, Augusta, Georgia
        Learning Objectives
        1. Anticipate the known types of chronic disability (motor, psychological, cognitive) after ischemic stroke and current approaches to reduce them.
        2. Identify the role of the cerebral vasculature in recovery after stroke.
        3. Predict which therapeutic targets will “bear fruit” in the reduction of post-stroke cognitive impairment.
        Scientific Poster Session, II: Anticoagulation Poster CPE
        October 27, 2019 12:45 PM

        Activity No. 0217-0000-19-210-L01-P; 0.50 contact hours.
        Knowledge Based Activity

          Learning Objectives
          1. Describe recent findings of research related to anticoagulation.
          2. Review four current anticoagulation research studies.

          Sun-2 Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in the Treatment of Portal Vein Thrombosis

          Sun-22 Direct oral anticoagulants compared to warfarin after Watchman™ device implantation

          Sun-23 Evaluating use of direct oral anticoagulants in patients with cardiac thrombus

          Sun-75 Safety and Efficacy of Direct Oral Anticoagulants in Extreme Body Weights

          Sun-127 Safety and efficacy of direct oral anticoagulants in abdominal transplant recipients

          Scientific Poster Session, II: Emergency Medicine Poster CPE
          October 27, 2019 1:30 PM

          Activity No. 0217-0000-19-211-L01-P; 0.50 contact hours.
          Knowledge Based Activity

            Learning Objectives
            1. Describe recent findings of research relevant to the practice of emergency medicine.
            2. Review findings from recent research relevant to clinical pharmacy practice in the emergency department.

            Sun-51 Impact of a pharmacist-led collaborative drug therapy management program for culture follow-up in an emergency department

            Sun-57 Evaluation of sepsis 1-hour bundle in the emergency department

            Sun-55 Evaluation of burnout syndrome among emergency medicine pharmacists

            Sun-71 Reducing 30-day readmissions and emergency department encounters while stratifying high risk patients in a care transitions program

            Sun-98 Introduction of a pharmacist-driven antimicrobial stewardship and culture follow-up program in the emergency department

            Sun-58 Predictors for extended spectrum beta-lactamase producing organisms in urine cultures of emergency department patients: An Exploratory Analysis

            Maintaining Healthy Work/Life Balance: How to Avoid Burnout While Sustaining Exceptional Performance, Part 1
            October 27, 2019 2:15 PM

            Activity No. 0217-0000-19-158-L04-P; 2.00 contact hours.

            • Moderator: Lindsay M. Arnold, Pharm.D., BCPS
              Clinical Pharmacy Manager PGY1 Residency Program Director St. Elizabeth's Medical Center Boston, Massachusetts

            Before the Burn: Defining Professional Burnout and its Scope
            • Speaker: Patrick J. Bridgeman, Jr., Pharm.D., BCPS
              Clinical Assistant Professor, Pharmacy Practice and Administration, Ernest Mario School of Pharmacy; Clinical Pharmacy Specialist - Emergency Medicine, Robert Wood Johnson University Hospital, New Brunswick, New Jersey
            Learning Objectives
            1. Describe the incidence and syndrome of professional burnout
            2. Identify risk factors for professional burnout.
            3. Explain the characteristics and utility of formal burnout assessments.

            Feeling the Burn: Identifying and Minimizing the Burden of Professional Burnout
            • Speaker: Paul O. Gubbins, Pharm.D., FCCP
              Associate Dean, Vice Chair & Professor, UMKC School of Pharmacy at MSU Division of Pharmacy Practice & Administration, University of Missouri-Kansas City, Springfield, Missouri
            Learning Objectives
            1. Describe short- and long-term consequences of professional burnout.
            2. Identify and address contributors to professional burnout among clinical faculty and practitioners.
            3. Identify symptoms of burnout in oneself and others.
            4. Identify steps to provide assistance and direction for colleagues and trainees at risk for burnout.

            Leadership Primer, II
            October 27, 2019 2:15 PM

            Activity No. 0217-0000-18-192-L04-P; 2.00 contact hours.
            Application Based Activity

            • Speaker: Robert E. Smith, Pharm.D.
              Professor Emeritus, Harrison School of Pharmacy, Auburn University, Auburn, Alabama
            • Speaker: Peter Hurd, Ph.D.
              Professor and Department Chair, Pharmaceutical and Administrative Sciences, St. Louis College of Pharmacy, St. Louis, Missouri
            Learning Objectives
            1. Describe the components of becoming a leader (Warren Bennis).
            2. Apply concepts and theories from the leadership literature to pharmacy settings.
            3. Describe the various attributes of leadership development.
            4. Apply concepts and theories from organizational behavior literature to pharmacy settings.
            5. Evaluate the use of principle-centered power in the pharmacy environment.
            Health Outcomes PRN Focus Session -- NIH Clinical and Translational Science Awards – Opportunities for Pharmacy Research
            October 27, 2019 2:15 PM

            Activity No. 0217-0000-19-177-L04-P; 1.50 contact hours.
            Application Based Activity

            • Moderator: Erin Weeda, Pharm.D., BCPS
              Assistant Professor, Medical University of South Carolina (MUSC), Charleston, South Carolina

            An Overview of the NIH Clinical and Translational Science Awards (CTSA) Program
            • Speaker: Bradley G. Phillips, Pharm.D., FCCP, BCPS
              Millikan-Reeve Professor and Head, Clinical and Administrative Pharmacy; Director, Clinical and Translational Research Unit, University of Georgia, Athens, Georgia
            Learning Objectives
            1. Describe the NIH CTSA program mechanism and overall goals
            2. Outline NIH CTSA program projects and initiatives.
            3. Discuss how the NIH CTSA program can support clinical pharmacy research.

            Using the NIH CTSA Program to Advance Pharmacy-based Translational Research
            • Speaker: Terry L. Seaton, Pharm.D., FCCP, BCPS
              Professor of Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, Missouri
            Learning Objectives
            1. Define translational research and describe how it applies to the pharmacy discipline.
            2. Discuss CTSA resources that could be used to support pharmacy-based translational research.

            How can the NIH CTSA Program Support Training and Career Development?
            • Speaker: Vicki L. Ellingrod, Pharm.D., FCCP
              Associate Dean for Research and Graduate Education and the John Gideon Searle Professor of Clinical and Translational Pharmacy, University of Michigan, Ann Arbor, Michigan
            Learning Objectives
            1. Outline CTSA opportunities for pharmacy students, residents, graduate students, and faculty.
            2. Describe how CTSA education, training, and career development opportunities may be useful in advancing research careers.

            Sharing Personal Experiences with the CTSA Program - How the CTSA Helped Move My Career Forward
            Learning Objectives
            1. Describe how CTSA resources were used to support personal research goals.
            2. Discuss an example of CTSA research from inception to completion, and share challenges encountered during the process.

            Hematology/Oncology PRN and Pharmaceutical Industry PRN Focus Session -- Biosimilars: An Extensive Review for the Clinical Pharmacist
            October 27, 2019 2:15 PM

            Activity No. 0217-0000-19-188-L04-P; 1.50 contact hours.
            Knowledge Based Activity

            • Moderator: Marco Martino, Pharm.D., MBA, BCPS, BCOP
              Operations Team Lead (Hematology/Oncology), Northwestern Medicine, Chicago, Illinois

            Evaluating Biosimilar Efficacy: Is It All the Same?
            • Speaker: Steven D. Lucio, Pharm.D., BCPS
              Vice President for the Center for Pharmacy Practice Excellence, Vizient, Irving, Texas
            Learning Objectives
            1. Outline the process by which biosimilar medications are developed and subsequently FDA-approved.
            2. Evaluate the official means to determine if a biosimilar medication is as effective as its brand-name medication.
            3. List the hematology/oncology biosimilar medications that are currently FDA-approved and are in the development pipeline.

            Show Me the Money: Biosimilar Formulary Decision-Making
            • Speaker: Maribel Pereiras, Pharm.D., BCOP
              Hematology/Oncology Pharmacy Specialist, Hackensack University Medical Center; Clinical Assistant Professor, Ernest Mario School of Pharmacy, Rutgers University, Hackensack, New Jersey
            Learning Objectives
            1. Discuss the process by which healthcare institutions should approve certain biosimilar medications for institution formularies.
            2. Describe the pharmacoeconomic impact biosimilar medications can have on an institution formulary.

            Pain and Palliative Care PRN Focus Session -- The State of the Science on Opioid Conversions
            October 27, 2019 2:15 PM

            Activity No. 0217-0000-19-212-L01-P; 1.50 contact hours.
            Knowledge Based Activity

            • Moderator: Kathryn A. Walker, Pharm.D., BCPS
              Senior Clinical Director of Palliative Care (MedStar Health), Associate Professor (University of MD School of Pharmacy)

            The Data Behind the Opioid Conversion Table Update- State of the Science
            • Speaker: Mary Lynn McPherson, Pharm.D., BCPS
              Professor, University of Maryland School of Pharmacy, Hospice Consultant Pharmacist, University of Maryland, Baltimore, Maryland
            Learning Objectives
            1. Discuss the evidence supporting the updated opioid conversion table.
            2. Defend the strengths and limitations of existing data related to opioid conversions.

            Health System Perspectives in Updating Opioid Conversion Tables
            • Speaker: Jessica E. Geiger-Hayes, Pharm.D.
              Clinical Pharmacist, Palliative Care, Riverside Methodist Hospital, Columbus, Ohio.
            • Speaker: Kristy T. Nguyen, Pharm.D., BCPS
              Clinical Pharmacist, Inland Valley Regional Medical Center, Wildomar, California
            Learning Objectives
            1. Describe three strategies utilized by health systems to successfully update the opioid table.
            2. Describe three barriers encountered by the targeted health systems and how they were overcome.

            Perioperative Care PRN Focus Session -- Red Light...Green Light...Red Light: Anticoagulation Challenges in the Surgical Patient
            October 27, 2019 2:15 PM

            Activity No. 0217-0000-19-178-L01-P; 1.50 contact hours.
            Application Based Activity

            • Moderator: Eric Johnson, Pharm.D., BCCCP
              Perioperative Critical Care Pharmacist, University of Kentucky HealthCare, Lexington, KY

            Re-doing the Undo: Resuming Oral Anticoagulation following Emergent Perioperative Reversal
            • Speaker: Audrey J. Littlefield, Pharm.D.
              Clinical Pharmacy Manager, Cardiothoracic ICU at NewYork-Presbyterian Hospital, Weill Cornell Medical Center
            Learning Objectives
            1. Identify potential barriers to resuming oral anticoagulation following emergent reversal.
            2. Evaluate surgical considerations for resuming oral anticoagulation following emergent reversal.
            3. Describe patient specific risks and benefits associated with resuming oral anticoagulation following emergent reversal.

            HIT-ing the Wall: Perioperative Management of Heparin-Induced Thrombocytopenia
            • Speaker: James S. Kalus, Pharm.D., FASHP
              Director of Pharmacy, Henry Ford Health System, Detroit, Michigan
            Learning Objectives
            1. Review the diagnosis, sequela and clinical duration of Heparin-Induced Thrombocytopenia.
            2. Identify appropriate heparin-alternatives in patients that require intraoperative anticoagulation.
            3. Describe potential adjunctive therapies that enable perioperative heparin use in patients with suspected HIT.

            Controlling Cost Hemorrhage: Pharmacoeconomic Mitigations of Cardiac Surgery
            • Speaker: Aaron J. Roberts, Pharm.D., BCPS
              Senior Clinical Pharmacist, UC Davis Health, Pharmacy Department, Sacramento, California
            Learning Objectives
            1. Compare evidence, efficacy and dosing option of lysine antagonists for hemostatic control during cardiac, thoracic or vascular surgery.
            2. Identify recombinant and endogenous coagulation products available for intraoperative use in the coagulopathic surgical patients.
            3. Define the role clinical pharmacists can play in establishing use criteria for perioperative hemostatics.

            Ambulatory Care PRN Focus Session -- Taking Your Patients’ Health to Heart: A Case-based Approach to Assess, Prevent, and Manage ASCVD
            October 27, 2019 4:00 PM

            Activity No. 0217-0000-19-179-L01-P; 1.50 contact hours.
            Application Based Activity

            • Moderator: Gregory Castelli, Pharm.D., BCPS, BC-ADM
              Assistant Professor, UPMC St. Margaret, Pittsburgh, Pennsylvania

            So You’re Saying There’s a Chance?! Estimating ASCVD Risk
            • Speaker: Elizabeth T. Renner, Pharm.D., BCPS, BCACP, CACP
              Clinical Pharmacist-Outpatient Cardiology at University of Michigan Health System, Ann Arbor, Michigan
            Learning Objectives
            1. Compare various calculators including the ACC/AHA Risk Estimator and the Pooled Cohort Equations to estimate ASCVD risk.
            2. Apply various ASCVD risk calculators to a standardized patient case.

            ASPIRINing for an Answer: Delving into the Latest Evidence on Aspirin for Primary Prevention
            • Speaker: Joel C. Marrs, Pharm.D., MPH, BCACP, BCCP, BCPS, CHC, CLS
              Associate Professor, University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy & Pharmaceutical Sciences, Aurora, Colorado
            Learning Objectives
            1. Discuss recent literature regarding aspirin use for primary prevention of ASCVD.
            2. Recommend judicious initiation, continuation and discontinuation of aspirin for primary prevention of ASCVD given patient specific factors.

            Evaluating the Updated 2018 ACC/AHA Cholesterol Guidelines
            • Speaker: Dave L. Dixon, Pharm.D., BCPS, FCCP
              Associate Professor, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia
            Learning Objectives
            1. Recall important updates to the 2018 version of the ACC/AHA cholesterol guidelines from previous versions.
            2. Critique the updated ACC/AHA cholesterol guideline recommendations to incorporating LDL thresholds using available literature.
            3. Evaluate the updated ACC/AHA cholesterol guideline recommendation of utilizing non-statin therapies for ASCVD prevention and treatment by reviewing available evidence.

            Question and Answer

            Drug Information PRN Focus Session -- Scholarship and Formulary Management Pearls for Your Practice and Research
            October 27, 2019 4:00 PM

            Activity No. 0217-0000-19-189-L04-P; 1.50 contact hours.
            Knowledge Based Activity

            • Moderator: Rena A. Gosser, Pharm.D., BCPS

              Clinical Pharmacy Manager, Harborview Medical Center, Seattle, WA

            Scholarship in Action: Strategies to Enhance Visibility, Impact, and Citations
            • Speaker: Jamie N. Brown, Pharm.D., BCPS, BCACP
              PGY2 Drug Information Residency Program Director & Drug Information/Investigational Drug Service Manager, Durham VA Health Care System, Durham, North Carolina
            Learning Objectives
            1. Describe methods for developing a manuscript that lead to improved visibility once the manuscript is published.
            2. Identify strategies to promote a professional publication and measure its impact through scholarship metrics.
            3. Assess resources available to maximize author visibility and impact.

            Biosimilars: Lucrative or Not?
            • Speaker: Gregory A. Heindel, Pharm.D., BCPS
              Medication Use Policy Pharmacist, UNC Health Care system, Charlotte, North Carolina
            Learning Objectives
            1. Describe the missed opportunities associated with the low uptake of biosimilars.
            2. Identify challenges that inhibit the adoption of biosimilars.

            Successful Strategies for Merging Multiple Formularies
            • Speaker: Angela Colella, Pharm.D.

            Learning Objectives
            1. Define the term formulary merger, types of formularies and pros and cons of merging formularies.
            2. Describe the process and discuss the different steps of formulary merger with roadblocks/potential solutions.
            3. List the different strategies of formulary merger and discuss their values/merits.
            4. Identify/Describe the different tools, resources and personnel required for the process from initiation to completion with approximate time frame.

            HIV PRN Focus Session -- Antiretroviral Care in 2019: Do the Numbers Matter?”
            October 27, 2019 4:00 PM

            Activity No. 0217-0000-19-213-L02-P; 1.50 contact hours.
            Application Based Activity

            • Moderator: Edward E. Grace, Pharm.D., BCPS-AQ ID
              President, Sovereign Medical Consulting, LLC, Greenville, South Carolina
            • Moderator: David B. Cluck, Pharm.D.
              Assistant Professor, Department of Pharmacy Practice, East Tennessee State University, Gatton College of Pharmacy, Johnson City, Tennessee

            Management of HIV in geriatrics
            • Speaker: Melissa Badowski, Pharm.D., BCPS, AAHIVP
              Clinical Associate Professor, Section of Infectious Diseases Pharmacotherapy, University of Illinois at Chicago, College of Pharmacy; Illinois Department of Corrections HIV Telemedicine, Chicago, Illinois
            Learning Objectives
            1. Identify the most common challenges in the management of HIV in geriatric patients.
            2. Evaluate the most common implications and solutions related to antiretroviral use in combination with other medications used in geriatric patients.
            3. Evaluate the role of injectable antiretrovirals in the suppression of HIV in adult patients.
            4. Define the role of 2-drug antiretroviral regimens in the management of HIV positive adult and geriatric patients.

            2- Versus 3-Drug Regimens for the Management of HIV in Adults – A Debate
            • Speaker: Elizabeth M. Sherman, Pharm.D.
              Associate Professor, Nova Southeastern University, College of Pharmacy, Fort Lauderdale, Florida; Division of Infectious Disease, Memorial Physician Group, Hollywood, Florida; Southeast AIDS Education and Training Center
            • Speaker: Kimberly Scarsi, Pharm.D., M.Sc.
              Associate Professor, University of Nebraska Medical Center, College of Pharmacy, Omaha, Nebraska
            Learning Objectives
            1. Identify patients who would and would not benefit from treatment simplification (eg change to DTG/RPV;DTG/DRV/r; DTG/3TC).
            2. Describe the role of 3TC/FTC in patients with the M184V mutation.
            3. iii. Identify the long-term risks and benefits of N(Nt)RTI inclusion (ABC, TDF, TAF) in chronic suppressive ART regimens.

            BCOP Clinical Session -- Anticoagulation Therapy: Considerations in the Setting of Malignancy
            October 27, 2019 4:00 PM

            Activity No. 0217-9999-19-160-L01-P; 2.00 contact hours.
            Application Based Activity

              Learning Objectives
              1. Discuss the suspected pathophysiology and problem of venous thromboembolism in malignancy.
              2. Describe current guidance for primary VTE prophylaxis in cancer patients.
              3. Analyze existing and emerging literature regarding the application of DOACs in the treatment of venous thromboembolism in malignancy.
              4. Assess issues related to DOAC use in malignancy and the impact they have on patient care.

              The Acquired Thrombophilia of Malignancy
              • Speaker: Amy S. Sipe, R.Ph.
                Clinical Pharmacy Specialist, Kansas City VA Medical Center, Kansas City, Missouri

              Primary VTE Prophylaxis in Outpatients with Cancer: Ready for primetime?
              • Speaker: Katerina Butler, Pharm.D., BCOP
                Hematology/Oncology Clinical Pharmacist, VA Salt Lake City Healthcare System, Salt Lake City, Utah

              The Changing Landscape of Anticoagulation Therapy for Cancer-Associated VTE
              • Speaker: Arthur L. Allen, Pharm.D., CACP
                Anticoagulation Program Manager, VA Salt Lake City Health Care System, Salt Lake City, Utah

              The Devil's in the Details: Therapeutic challenges facing the anticoagulated cancer patient.
              • Speaker: Katerina Butler, Pharm.D., BCOP
                Hematology/Oncology Clinical Pharmacist, VA Salt Lake City Healthcare System, Salt Lake City, Utah

              Debate: Should DOACs be used to treat cancer-associated VTE in patients with primary GI/GU cancer?
              • Speaker: Amy S. Sipe, R.Ph.
                Clinical Pharmacy Specialist, Kansas City VA Medical Center, Kansas City, Missouri
              • Speaker: Arthur L. Allen, Pharm.D., CACP
                Anticoagulation Program Manager, VA Salt Lake City Health Care System, Salt Lake City, Utah

              Panel Discussion

              Maintaining Healthy Work/Life Balance: How to Avoid Burnout While Sustaining Exceptional Performance, Part 2
              October 27, 2019 4:15 PM

              Activity No. 0217-0000-19-159-L04-P; 2.00 contact hours.
              Application Based Activity

              • Moderator: Lindsay M. Arnold, Pharm.D., BCPS
                Clinical Pharmacy Manager PGY1 Residency Program Director St. Elizabeth's Medical Center Boston, Massachusetts

              Help or Harm: Managers as a Contributor or Solution to Burnout
              • Speaker: Kelly C. Lee, Pharm.D., FCCP, BCPP
                Professor of Clinical Pharmacy, University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, California
              Learning Objectives
              1. Describe strategies to reduce burnout for learners and practitioners in new and unfamiliar roles.
              2. Develop a proactive plan to minimize professional burnout in new employees and learners.
              3. Addressing role of professional burnout on job satisfaction, retention and turnover, and productivity.
              4. Describe management response to professional burnout.
              5. Provide tips on maintaining high standards in a demanding work environment.

              Establishing a Meaningful Work/Life Balance: Expert Panel Discussion
              • Speaker: Patrick J. Bridgeman, Jr., Pharm.D., BCPS
                Clinical Assistant Professor, Pharmacy Practice and Administration, Ernest Mario School of Pharmacy; Clinical Pharmacy Specialist - Emergency Medicine, Robert Wood Johnson University Hospital, New Brunswick, New Jersey
              • Speaker: Paul O. Gubbins, Pharm.D., FCCP
                Associate Dean, Vice Chair & Professor, UMKC School of Pharmacy at MSU Division of Pharmacy Practice & Administration, University of Missouri-Kansas City, Springfield, Missouri
              • Speaker: Kelly C. Lee, Pharm.D., FCCP, BCPP
                Professor of Clinical Pharmacy, University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, California
              Learning Objectives
              1. Identify challenges to maintaining ideal work/life balance
              2. Describe strategies for achieving ideal work/life balance.
              3. List work/life balance preservation tips and activities that can be incorporated into day-to-day professional activities.

              Pediatrics PRN Focus Session -- Medical Use of Cannabinoid Products in the Pediatric Population
              October 27, 2019 4:30 PM

              Activity No. 0217-0000-19-180-L01-P; 1.50 contact hours.
              Application Based Activity

                Medical Use of Cannabinoids in Epilepsy and Beyond
                • Speaker: Christopher T. Campbell, Pharm.D., BCPPS
                  Clinical Assistant Professor, University of Florida, Gainesville, Florida
                Learning Objectives
                1. Describe the use of cannabidiol oil and FDA-approved solution in management of epilepsy.
                2. Discuss the data and current trends in off-label use of the FDA-approved cannabidiol solution.
                3. Identify cannabinoids’ role in the management of chronic conditions and orphan disease states.
                4. List other cannabinoid pharmaceuticals currently under development.

                Safe by Nature? Concerns with the Medical Use of Cannabinoids
                • Speaker: Lisa Garrity, Pharm.D., BCPS
                  Pharmacy Clinical Specialist in Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
                Learning Objectives
                1. Identify potential developmental concerns with the use of cannabinoids in children and adolescents.
                2. Distinguish the adverse effects associated with the use of specific cannabinoid derivatives in a given patient case.
                3. Analyze potential interactions between cannabinoids and other pharmaceuticals for a given patient case.

                Addressing Logistical Issues with the Medical Use of Cannabinoids
                • Speaker: Michael W. Barberio, Pharm.D., BCPPS
                  Emergency Medicine Clinical Pharmacist Specialist, Children's Hospital Colorado, Aurora, Colorado
                Learning Objectives
                1. List strategies to address issues surrounding medical use of cannabinoids in healthcare facilities.
                2. Discuss the effects of state legislations on medical use of cannabinoids.
                3. Describe current approaches to obtain third-party coverage for labeled and unlabeled use of the FDA-approved cannabidiol solution.
                4. Collect ideas and solutions for implementing at own practice-site through small group discussions revolving around logistics of medical cannabinoids use.

                BCOP Clinical Session -- Updates in the Management of Acute, Chronic, and Refractory Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
                October 28, 2019 8:00 AM

                Activity No. 0217-9999-19-172-L01-P; 2.00 contact hours.
                Application Based Activity

                  Learning Objectives
                  1. Describe the mechanism of action of CTLA-4, PD-1, and PD-L1 inhibitors and how their differences contribute to their respective immune-related adverse event profile.
                  2. Evaluate the safety and efficacy data available for current FDA approved immunotherapy agents and treatment regimens.
                  3. Design a customized treatment plan for a patient presenting to the acute care inpatient service with a severe or life-threatening irAE.
                  4. Design a customized treatment plan for a patient presenting to an ambulatory outpatient clinic with a chronic or steroid refractory irAE.
                  5. Reccomend effective approaches to care coordination and survivorship planning for patients who experience irAE across a healthcare system.

                  Introduction
                  • Speaker: Eve-Michelle Segal, Pharm.D., BCOP
                    Lead Clinical Pharmacist, University of Washington Medical Center/Seattle Cancer Care Alliance; Clinical Instructor, University of Washington School of Pharmacy, Seattle, Washington

                  Immunotherapy Agents in Oncology
                  • Speaker: Joseph S. Bubalo, Pharm.D., BCPS, BCOP
                    Oncology Clinical Pharmacy Specialist, OHSU Hospital and Clinics, Portland, Oregon

                  Differential Diagnosis and Treatment of Immune-related Adverse Effects in the Acute Care Setting
                  • Speaker: Joseph S. Bubalo, Pharm.D., BCPS, BCOP
                    Oncology Clinical Pharmacy Specialist, OHSU Hospital and Clinics, Portland, Oregon

                  Differential Diagnosis and Treatment of Immune-related Adverse Effects in the Ambulatory Care Setting
                  • Speaker: Carolyn J. Oxencis, Pharm.D., BCOP
                    Hematology/Oncology Clinical Pharmacist, Froedtert and the Medical College of Wisconsin Clinical Cancer Center, Milwaukee, Wisconsin

                  Interprofession Collaboration to Develop irAE Treatment Algorithms and Survivorship Plans
                  • Speaker: Carolyn J. Oxencis, Pharm.D., BCOP
                    Hematology/Oncology Clinical Pharmacist, Froedtert and the Medical College of Wisconsin Clinical Cancer Center, Milwaukee, Wisconsin

                  Question and Answer

                  Wrap-Up and Conclusions

                  Research and Scholarship Academy Abstract Workshop
                  October 28, 2019 8:30 AM

                  Activity No. 0217-0000-19-223-L04-P; 2.00 contact hours.
                  Knowledge Based Activity

                  • Speaker: Jimmi Hatton Kolpek, Pharm.D., FCCP, FCCM, FNAP
                    Professor of Pharmacy, College of Pharmacy, Department of Pharmacy Practice and Science, University of Kentucky, Lexington, Kentucky
                  • Speaker: Jeremy Thomas, Pharm.D.
                    Associate Professor, Department of Pharmacy, University of Arkansas for Medical Sciences, College of Pharmacy, Little Rock, Arkansas
                  • Speaker: Sandra L. Kane-Gill, Pharm.D., M.Sc., FCCP, FCCM
                    Professor of Pharmacy and Therapeutics, University of Pittsburgh, School of Pharmacy, Pittsburgh, Pennsylvania
                  • Speaker: Gary L. Cochran, Pharm.D., S.M.
                    Associate Professor of Pharmacy Practice, University of Nebraska Medical Center, College of Pharmacy, Omaha, Nebraska
                  • Speaker: Jacqueline McLaughlin, Ph.D., M.S.
                    Assistant Professor, Educational Innovation and Research; Director, Office of Strategic Planning and Assessment, University of North Carolina Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
                  Learning Objectives
                  1. Review abstract criteria (Instructions, Structure) for Original Research, Systematic Review/Meta-Analysis, Case Reports, and Clinical Pharmacy Forum.
                  2. Describe the impact of abstract categories and review criteria on successful abstract submissions.
                  3. Identify common pitfalls in abstract submissions using sample abstracts and review criteria.
                  4. Review abstracts in cross-sectional surveys, observational, educational and implementation science with R & S Faculty
                  Department of Veterans Affairs Clinical Pharmacy Practice: Forging the Pathway for Integration of the Clinical Pharmacist into Comprehensive Medication Management
                  October 28, 2019 8:30 AM

                  Activity No. 0217-0000-19-214-L04-P; 1.50 contact hours.
                  Knowledge Based Activity

                    VHA Clinical Pharmacy Practice: From Creation to Current Practice
                    • Speaker: Anthony P. Morreale, Pharm.D.
                    Learning Objectives
                    Review the VA Clinical Pharmacist as an advanced care provider providing comprehensive medication management
                    Describe current policy that has led to standardization of VA Clinical Pharmacy Practice credentialing, scope of practice, and professional practice evaluation.

                    VHA Clinical Pharmacy Practice: Future Opportunities for CMM Standardization
                    • Speaker: M. Shawn McFarland, Pharm.D., BCPS, BCACP, BC-ADM
                      Associate Service Chief of Pharmacy, Clinical & Educational Programs, Clinical Pharmacy Specialist Primary Care; Residency Program Director-PGY-2 Ambulatory Care Residency, VA Tennessee Valley Healthcare System, Alvin C. York Campus; Associate Professor, University of Tennessee College of Pharmacy, Murfreesboro, Tennessee
                    Learning Objectives
                    Discuss current foundational efforts on promoting CMM practice management standardization.
                    Outline future CMM opportunities and integration of the VA clinical pharmacist into Veteran Care.

                    Clinical Reasoning Series in Critical Care Pharmacy - Managing Cardiovascular Therapies in the Critically Ill Part 1
                    October 28, 2019 8:30 AM

                    Activity No. 0217-0000-19-231-L01-P; 3.00 contact hours.
                    Knowledge Based Activity

                      Learning Objectives
                      Describe skills to consider in initiating individualized pharmacotherapy
                      Describe the risk assessment and initiating a antithrombotic prophylaxis or treatment management plan
                      Describe when and how to approach the pharmacologic management of Atrial Fibrillation
                      Explain the process of evaluating and initiating Thrombolytic therapy (non-Stroke setting)
                      Describe the impact of unique patient characteristics that may lead to modified management plans in the setting of going into and out of acute Heart Failure
                      Identify pharmacologic agents used in the acute management and impact of acute failure on other therapies
                      Describe considerations for individualizing therapy in special populations

                      Introduction/Skills for Initiating and individualizing Therapy/Case Presentation
                      • Speaker: William E. Dager, Pharm.D., FCCP, BCPS
                        Pharmacist Specialist, Department of Pharmaceutical Services, University of California Davis Medical Center, Sacramento, California

                      Preventing and Treating Acute Thromboembolism
                      • Speaker: Christopher Michaud, Pharm.D., BCCCP, BCPS
                        Clinical Pharmacy Specialist, Cardiothoracic ICU, Spectrum Care, Grand Rapids, Michigan

                      Atrial Fibrillation Stroke Prevention
                      • Speaker: Craig J. Beavers, Pharm.D., FAHA, BCPS-AQ Cardiology, AACC, CACP
                        Director of Cardiovascular Services, Baptist Health Paducah;Cardiovascular Clinical Pharmacist, University of Kentucky HealthCare, Lexington, Kentucky; Assistant Adjunct Professor, University of Kentucky College of Pharmacy, Lexington, Kentucky

                      Embolic Events and use of Thrombolysis
                      • Speaker: Eric W. Mueller, Pharm.D., FCCM, FCCP
                        Assistant Director of Clinical Pharmacy Services and Research, University of Cincinnati Medical Center, Cincinnati, Ohio; Adjunct Associate Professor of Pharmacy Practice and Administrative Sciences, University of Cincinnati, Cincinnati, Ohio

                      Break

                      Acute Heart Failure Management
                      • Speaker: Alana M. Ciolek, Pharm.D.
                        Cardiothoracic Intensive Care Clinical Pharmacy Specialist, New York-Presbyterian Hospital, New York, New York

                      Special Populations – Critically Ill, Obesity and Renal Failure
                      • Speaker: William E. Dager, Pharm.D., FCCP, BCPS
                        Pharmacist Specialist, Department of Pharmaceutical Services, University of California Davis Medical Center, Sacramento, California

                      Panel Discussion of Cases

                      BCACP and BCGP Clinical Session -- How Low Do You Go? Applying the 2018 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines to Individual Patients
                      October 28, 2019 8:30 AM

                      Activity No. 0204-9999-19-270-L01-P; 1.00 contact hour.
                      Application Based Activity

                      • Speaker: Eric J. MacLaughlin, Pharm.D., FASHP, FCCP, BCPS
                        Professor and Chair, Department of Pharmacy Practice Professor, Departments of Family Medicine and Internal Medicine Texas Tech University Health Sciences Center, Amarillo, Texas
                      Learning Objectives
                      1. Compare and contrast the therapeutic goals in the 2013 and 2018 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for management of blood cholesterol.
                      2. Evaluate a patient’s risk of cardiovascular disease using traditional means and taking into consideration “risk-enhancing factors”.
                      3. Design patient-centered cholesterol treatment plans in complex patients with dyslipidemia.
                      Reinventing Yourself: “Old” Drugs with “New” Uses
                      October 28, 2019 9:00 AM

                      Activity No. 0217-0000-19-163-L01-P; 1.50 contact hours.
                      Application Based Activity

                      • Moderator: Alyssa M. Peckham, Pharm.D., BCPP
                        Assistant Professor and Clinical Addiction Specialist, Northeastern University, Bouvé College of Health Sciences, School of Pharmacy, Boston, Massachusetts

                      Gabapentin Abuse: A “Neu Pain” for Clinicians
                      • Speaker: Kirk E. Evoy, Pharm.D., BCACP, BC-ADM, CTTS
                        Clinical Assistant Professor, College of Pharmacy, The University of Texas at Austin; Adjunct Assistant Professor, School of Medicine, The University of Texas Health San Antonio; Ambulatory Care Pharmacist, Southeast Clinic, University Health System
                      Learning Objectives
                      1. Identify abuse potential of gabapentin and trends in the prevalence of gabapentin abuse, both globally and nationally, and with or without opioids.
                      2. Compare and contrast medical harm and healthcare utilization rates resulting from gabapentin-only abuse versus gabapentin abuse with concomitant opioids.
                      3. Distinguish patients with the highest risk of future gabapentin abuse based on comorbid conditions and concomitant medications.
                      4. Evaluate state-level and national legislative efforts assisting healthcare personnel in identifying and mitigating gabapentin abuse.

                      New Indications for Medical Marijuana: Weeding Through the Evidence
                      • Speaker: Ann M. Philbrick, Pharm.D., FCCP, BCPS, BCACP
                        Associate Professor, University of Minnesota College of Pharmacy, Minneapolis, Minnesota; Bethesda Family Medicine Clinic, Saint Paul, Minnesota
                      Learning Objectives
                      1. Discuss the pharmacology of medical marijuana and proposed therapeutic mechanism of action.
                      2. Identify potential medical conditions for which medical marijuana may be useful.
                      3. Recognize potential adverse effects of medical marijuana and develop appropriate patient counseling points.

                      Ketamine for MDD and PTSD: Analyzing the “Psych” in Psychedelic
                      • Speaker: Jessica E. Geiger-Hayes, Pharm.D.
                        Clinical Pharmacist, Palliative Care, Riverside Methodist Hospital, Columbus, Ohio.
                      Learning Objectives
                      1. Discuss the potential role of ketamine in the treatment of PTSD and MDD.
                      2. Review the current scientific evidence of ketamine therapy for treatment of PTSD and MDD.
                      3. Evaluate the common clinical barriers to treatment with ketamine infusions.

                      Balancing the Pharmacy School Bubble
                      October 28, 2019 9:00 AM

                      Activity No. 0217-0000-19-161-L04-P; 1.50 contact hours.
                      Knowledge Based Activity

                      • Moderator: Kalen B. Manasco, Pharm.D., BCPS, AE-C
                        Clinical Professor and Division Head, Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, Florida

                      Fact or Fiction: Is the Pharmacy School Bubble Ready to Burst?
                      • Speaker: Daniel L. Brown, Pharm.D.
                        Associate Dean,South University School of Pharmacy Columbia, South Carolina
                      Learning Objectives
                      1. Review the current trends in pharmacy school admissions programs in the US.
                      2. Describe the factors contributing to the increased growth in pharmacy school programs.
                      3. Examine the overall challenges of increasing academic standards within US pharmacy schools.

                      Pharmacy School Bubble: Impact on Post-Graduate Programs and Professional Opportunities
                      • Speaker: Frank P. Paloucek, Pharm.D., DABAT, FASHP
                        Clinical Professor in Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, Chicago, Illinois
                      Learning Objectives
                      1. Discuss the impact of the pharmacy school growth on post-graduate education and professional opportunities.
                      2. Identify strengths and opportunities for postgraduate programs and professional environments to capitalize on.
                      3. Explore strategies for addressing the challenges in post-graduate programs and professional environments.

                      Quality vs. Quantity: An A to Z Approach to Documenting, Evaluating, and Sharing Clinical Pharmacy Performance Outcome Metrics
                      October 28, 2019 9:00 AM

                      Activity No. 0217-0000-19-162-L04-P; 1.50 contact hours.
                      Application Based Activity

                      • Moderator: Kelly M. Rudd, Pharm.D., FCCP, BCPS
                        Director, Network Pharmacy Services & Clinical Pharmacy Specialist, Anticoagulation Bassett Healthcare Network – Bassett Medical Center, Cooperstown, New York
                      • Speaker: Curtis E. Haas, Pharm.D., FCCP, BCPS
                        Director of Pharmacy, University of Rochester Medical Center, Rochester, New York
                      • Speaker: Travis B. Dick, Pharm.D., MBA, BCPS
                        Associate Director of Clinical Pharmacy Services, University of Rochester Medical Center, Rochester, New York Director, PGY1 Pharmacy Residency, University of Rochester Medical Center, Rochester, New York

                      State of the Dashboard: Clinical and Administrative Perspectives
                      Learning Objectives
                      1. Describe the clinical dashboard and its application to clinical pharmacy services.
                      2. Determine which metrics are relevant for various stakeholders within an institution.
                      3. Describe how to align institutional, professional and stakeholder needs with available metrics.

                      Design and Collect: Creating an Efficient Dashboard
                      Learning Objectives
                      1. Describe how to mine the electronic health record (EHR) to populate dashboard.
                      2. Choose appropriate metrics to support capture of healthcare reimbursement for both the current and evolving reimbursement landscape.
                      3. Describe strategies to efficiently operationalize, and/or modify, existing metrics or dashboard data.

                      Evaluate and Disseminate: Making Effective Use of Clinical Dashboard Data
                      Learning Objectives
                      1. Identify strategies to use dashboard data to demonstrate clinical pharmacists’ value as specific to the various stakeholders (colleagues, operational, patients, C-suite, etc.).
                      2. Describe how to use dashboard data to maximizing quality and efficiency of service delivery when human and/or financial resources may be limited.
                      3. Identify strategies to utilize dashboard data to justify additional human resources for and/or development new clinical services for programs with high return on investment (ROI) potential and those with high value but, potentially low ROI.

                      Panel Discussion/Ask the Experts
                      Learning Objectives
                      1. Identify how the speakers may have struggled individually, and how coming together helped them resolve issues and break down barriers.
                      2. Describe strategies to overcome challenges and barriers to implementation within the department and organization and the use of quality measure analyses.
                      3. Identify and collegially discuss practice- and clinician-specific queries.

                      BCACP and BCGP Clinical Session -- JNC8 versus 2017 ACC/AHA Hypertension Guidelines: Which Should We Follow?
                      October 28, 2019 9:30 AM

                      Activity No. 0204-9999-19-303-L01-P; 1.50 contact hours.
                      Application Based Activity

                      • Speaker: Nicholas Leon, Pharm.D., BCPS, BCACP, FCPP
                        Associate Professor of Pharmacy Practice, Thomas Jefferson University, Jefferson College of Pharmacy, Philadelphia, Pennsylvania
                      • Speaker: Kristin Watson, Pharm.D., BCPS
                        Associate Professor, University Of Maryland School of Pharmacy, Baltimore, Maryland
                      Learning Objectives
                      1. Evaluate the recommendations for management of hypertension in adults from the eighth Joint National Committee (JNC 8) and the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines.
                      2. Apply the evidence-based recommendations in the current guidelines for the management of hypertension to specific patient cases, including geriatric patients.
                      3. In collaboration with an interprofessional team, devise pharmacotherapeutic plans for adults with hypertension based on current evidence-based guidelines and recent literature.
                      Scientific Poster Session, III: Vancomycin/Infectious Disease Poster CPE
                      October 28, 2019 10:30 AM

                      Activity No. 0217-0000-19-215-L01-P; 0.50 contact hours.
                      Knowledge Based Activity

                        Learning Objectives
                        1. Describe pharmacists’ optimization of vancomycin use in clinical practice.
                        2. Describe antimicrobial stewardship as it relates to the use of vancomycin in contemporary pharmacy practice.

                        Mon AM-73 Impact of a pharmacist driven vancomycin de-escalation guideline

                        Mon AM-67 Empiric Vancomycin for Community-Acquired Meningitis in Adults: A Single-Center Retrospective Analysis of Need and Risk

                        Mon AM-70 Evaluation of risk factors and clinical outcomes of patients with vancomycin-resistant Enterococcus infections

                        Mon AM-72 Impact of area-under-the-curve monitoring for vancomycin on incidence of acute kidney injury in orthopedic patients

                        Mon AM-109 Evaluate serum trough vancomycin levels in pediatric inpatients

                        Mon AM-128 Evaluation of Vancomycin Pharmacokinetics in End Stage Liver Disease

                        Scientific Poster Session, III: Pharmacogenomics Poster CPE
                        October 28, 2019 11:00 AM

                        Activity No. 0217-0000-19-216-L01-P; 0.50 contact hours.
                        Knowledge Based Activity

                          Learning Objectives
                          1. Review the concept of pharmacogenetics and pharmacogenomics.
                          2. Discuss examples of how pharmacogenomics can lead to individualization of drug therapy.

                          Mon AM-116 Establishment and utilization of pharmacogenomics econsults at Mayo Clinic

                          Mon AM-125 Implementation of a Pharmacogenomics Service in an Academic Family Medicine Clinic

                          Mon AM-120 Implementation of Pharmacogenomic Services for Patients with Refractory Psychiatric or Neurologic Disorders

                          Mon AM-117 Differences in predicted warfarin dosing requirements for Hmong versus East Asians using a genotype-based dosing algorithm

                          Mon AM-121 Pharmacists Attitudes and Knowledge of Pharmacogenetics in a Large, Multi-state, Healthcare System

                          Mon AM-119 Discrepancies in Clinical Guidance to Manage Drug-Gene Interactions: Analysis of Recommendations from Prominent U.S. Guidance Sources

                          Mon AM-118 Evaluation of CPIC Level A Drug Prescribing in IGNITE-Affiliated Health Systems: Opportunity for Pharmacogenomics Implementation Among Adult Patients

                          Mon AM-123 Patient's Perspectives about Psychiatric Pharmacogenetic Testing

                          Mon AM-122 Providers’ experiences and perspectives with psychiatric pharmacogenomic testing

                          BCACP and BCGP Clinical Session -- When Life Happens: Managing Diabetes in the Older Adult Across the Continuum of Care
                          October 28, 2019 11:00 AM

                          Activity No. 0204-9999-19-246-L01-P; 1.50 contact hours.
                          Application Based Activity

                          • Speaker: Amie Taggart Blaszczyk, Pharm.D., CGP, BCPS
                            Associate Professor and Division Head – Geriatrics, Texas Tech University School of Pharmacy, Dallas, Texas
                          • Speaker: Dana G. Carroll, Pharm.D., BCGP, BCPS, CDE
                            Clinical Professor, Auburn University Harrison School of Pharmacy, Auburn, Alabama
                          Learning Objectives
                          1. Design a treatment regimen for an older adult with diabetes mellitus taking into consideration therapeutic goals and other patient-related variables.
                          2. Develop a care plan for an older adult patient with diabetes mellitus who is making the transition from one geriatric care setting to another.
                          3. Summarize the safety and administration concerns with diabetes medications that should be communicated to patients, caregivers and related healthcare providers across the spectrum of geriatric care settings.
                          4. Evaluate the evidence base for the use of diabetic medications in the older adult.
                          5. Generate practical advice for their use of these agents in this patient population.
                          Scientific Poster Session, IV: Pain Management Poster CPE
                          October 28, 2019 1:00 PM

                          Activity No. 0217-0000-19-217-L01-P; 0.50 contact hours.
                          Knowledge Based Activity

                            Learning Objectives
                            1. Discuss current and relevant research involving pain management/analgesia.
                            2. Review four current pain management/analgesia research studies important to clinical pharmacy.

                            Mon PM-133 Pain control during the IV opioid shortage -- a natural experiment

                            Mon PM-106 Does early physical therapy intervention reduce opioid burden and improve functionality in the management of chronic lower back pain?

                            Mon PM-107 We have clinical pharmacists in the pain clinic, but what do they do?

                            Mon PM-111 Medicine in search of evidence: the use of acetaminophen in patients receiving strong opioids for cancer pain

                            Mon PM-109 Evaluating the Effectiveness and Safety of Ketamine in Refractory Pain on the Palliative Care Service

                            Mon PM-127 Feasibility and Potential of Mobile Health for Pain Management and Education in Kidney Transplants

                            Clinical Reasoning Series in Critical Care Pharmacy - Managing Cardiovascular Therapies in the Critically Ill Part 2
                            October 28, 2019 1:00 PM

                            Activity No. 0217-0000-19-232-L01-P; 3.00 contact hours.
                            Knowledge Based Activity

                              Learning Objectives
                              Describe skills that can be utilized to measure and adapt therapy to meet management goals
                              Describe selected coagulopathic situations including liver failure and HIT
                              Identify various agents used to reverse the effects of anticoagulants and antiplatelet agents
                              Explain how anticoagulants and Antiplatelet agents are managed around invasive procedures
                              Describe considerations for managing thrombosis and bleeding in patients with a LVAD/Impella or cardiac valve
                              Explain the ECLS circuit and pharmacologic management considerations

                              Introduction/Skills for revising therapies and adapting to advances in technology/Case presentation.
                              • Speaker: William E. Dager, Pharm.D., FCCP, BCPS
                                Pharmacist Specialist, Department of Pharmaceutical Services, University of California Davis Medical Center, Sacramento, California

                              Coagulopathies, HIT, and Hemorrhagic Emergencies
                              • Speaker: Eric W. Mueller, Pharm.D., FCCM, FCCP
                                Assistant Director of Clinical Pharmacy Services and Research, University of Cincinnati Medical Center, Cincinnati, Ohio; Adjunct Associate Professor of Pharmacy Practice and Administrative Sciences, University of Cincinnati, Cincinnati, Ohio

                              Reversing Anticoagulation and Antiplatelet Agents
                              • Speaker: William E. Dager, Pharm.D., FCCP, BCPS
                                Pharmacist Specialist, Department of Pharmaceutical Services, University of California Davis Medical Center, Sacramento, California

                              Intra/Peri-operative Anticoagulation and Hemorrhagic Emergencies
                              • Speaker: Craig J. Beavers, Pharm.D., FAHA, BCPS-AQ Cardiology, AACC, CACP
                                Director of Cardiovascular Services, Baptist Health Paducah;Cardiovascular Clinical Pharmacist, University of Kentucky HealthCare, Lexington, Kentucky; Assistant Adjunct Professor, University of Kentucky College of Pharmacy, Lexington, Kentucky

                              Break

                              Mechanical Devices – LVAD/Impella/Cardiac Valves
                              • Speaker: Alana M. Ciolek, Pharm.D.
                                Cardiothoracic Intensive Care Clinical Pharmacy Specialist, New York-Presbyterian Hospital, New York, New York

                              ECLS Considerations
                              • Speaker: Christopher Michaud, Pharm.D., BCCCP, BCPS
                                Clinical Pharmacy Specialist, Cardiothoracic ICU, Spectrum Care, Grand Rapids, Michigan

                              Panel Discussion of Cases

                              The Habits of Preceptors Rubric: The Intentional Pursuit of Developing and Refining Positive Precepting Habits Spanning Nascent to Polished Preceptors
                              October 28, 2019 1:15 PM

                              Activity No. 0217-0000-19-218-L04-P; 2.00 contact hours.
                              Knowledge Based Activity

                              • Speaker: Lindsay Davis, Pharm.D., BCPS, ASH-CHC, TTS, FAzPA
                                Associate Professor, Midwestern University College of Pharmacy, Glendale, Arizona
                              Learning Objectives
                              1. Explain the concept of the “Habits of Preceptors Rubric” (HOP-R) in terms of its goal to improve preceptor skill and learning outcomes.
                              2. Utilize the HOP-R to self-assess precepting habits in Domains 2 (Preceptor is an effective educator) and 3 (Preceptor provides high-quality assessment of learners).
                              3. Create a continuous professional development plan consisting of three SMART goals focused on precepting skill development.
                              Scientific Poster Session, IV: Transitions of Care Poster CPE
                              October 28, 2019 1:30 PM

                              Activity No. 0217-0000-19-219-L04-P; 0.50 contact hours.
                              Knowledge Based Activity

                                Learning Objectives
                                1. Describe recent findings of research relevant to clinical pharmacist involvement in the transition of care in various clinical settings.
                                2. Review four research studies involving transitions of care important to clinical pharmacy.

                                Mon PM-8 Effect of a standardized pharmacist transitions of care intervention on chronic obstructive pulmonary disease outcomes

                                Mon PM-13 Evaluation of a Pharmacist-Driven Post-Stroke Transitions of Care Clinic on 30 and 90-Day Hospital Readmission Rates

                                Mon PM-73 Improving transitions from hospital to home through expanded discharge communication

                                Mon PM-118 The impact of pharmacogenomics transitions of care: downstream prescribing after inpatient pharmacogenomics service consultation

                                Mon PM-4 An Innovative Transitions of Care (TOC) Model Incorporating Pharmacy Services by Leveraging Telehealth

                                Personal Leadership Development
                                October 28, 2019 1:45 PM

                                Activity No. 0217-0000-18-204-L04-P; 4.00 contact hours.
                                Application Based Activity

                                • Speaker: Peter Hurd, Ph.D.
                                  Professor and Department Chair, Pharmaceutical and Administrative Sciences, St. Louis College of Pharmacy, St. Louis, Missouri
                                • Speaker: Robert E. Smith, Pharm.D.
                                  Professor Emeritus, Harrison School of Pharmacy, Auburn University, Auburn, Alabama
                                Learning Objectives
                                1. Describe the importance of taking personal responsibility for self-leadership in developing leadership capabilities.
                                2. Describe ways that you can be proactive when working with others in various settings, such as performance evaluation.
                                3. Produce the start of a personal mission statement, applying to both personal and work-related areas of your life.
                                4. Apply time management strategies, based on your mission statements, to your personal and professional leadership challenges
                                PSAP Live: Optimizing Treatment with Antidepressants and Antipsychotics
                                October 28, 2019 1:45 PM

                                Activity No. 0217-0000-19-190-L01-P; 1.50 contact hours.
                                Application Based Activity

                                • Moderator: Mary Wun-Len Lee, Pharm.D., FCCP, BCPS

                                  Vice President and Special Assistant to the President, Midwestern University; Professor of Pharmacy Practice, Chicago College of Pharmacy, Downers Grove, Illinois

                                • Speaker: Sarah E. Grady, Pharm.D., BCPS, BCPP

                                  Associate Professor of Clinical Sciences, Drake University College of Pharmacy and Health Sciences, Des Moines, Iowa

                                • Speaker: Archana Jhawar, Pharm.D., BCPP

                                  Assistant Professor, University of Illinois at Chicago; Clinical Psychiatric Pharmacist, Jesse Brown VAMC, Chicago, Illinois

                                • Speaker: Brittany L. Parmentier, BCPS, BCPP

                                  Clinical Assistant Professor, University of Texas at Tyler Fisch College of Pharmacy, Tyler, Texas

                                Learning Objectives
                                1. Analyze therapeutic options for partial response to antidepressants and treatment-resistant depression.
                                2. Develop a treatment plan for the management of antidepressant-associated adverse effects.
                                3. Evaluate and recommend appropriate monitoring parameters for all antipsychotic agents.
                                Adult Medicine PRN Focus Session -- Post-Op Debate: Anticoagulation vs. Aspirin for VTE Prophylaxis Following Orthopedic Surgery
                                October 28, 2019 1:45 PM

                                Activity No. 0217-0000-19-181-L01-P; 1.50 contact hours.
                                Application Based Activity

                                • Moderator: Ryan E. Owens, Pharm.D., BCPS
                                  Assistant Professor, Department of Pharmacy Practice, Wingate University School of Pharmacy, Wingate, North Carolina

                                Setting the Stage: Causes and Prevention of Postoperative VTE Development
                                • Speaker: Rachel C. Wolfe, Pharm.D., BCCCP
                                  Clinical Pharmacy Specialist of Perioperative Services, Barnes-Jewish Hospital, Saint Louis, Missouri
                                Learning Objectives
                                1. Review the pathophysiology involved in VTE development.
                                2. Identify risk factors for VTE development in the postoperative period.
                                3. Describe the evolving nature of postoperative VTE prophylaxis guideline recommendations.

                                Postoperative Prophylaxis Stance: Anticoagulation versus Aspirin
                                • Speaker: Jennifer Twilla, Pharm.D.,BCPS
                                  Assistant Professor, Methodist University Hospital, University of Tennessee, Memphis, Tennessee
                                • Speaker: Paul P. Dobesh, Pharm.D., FCCP, BCPS, BCCP
                                  Professor of Pharmacy Practice, College of Pharmacy University of Nebraska Medical Center, Omaha, Nebraska
                                Learning Objectives
                                1. Evaluate efficacy and safety of aspirin vs. anticoagulation for VTE prophylaxis following orthopedic surgery.
                                2. Compare and contrast strengths and weaknesses of using aspirin vs. anticoagulation for VTE prophylaxis following orthopedic surgery.
                                3. Identify potential risks and benefits of utilizing aspirin vs. anticoagulation for VTE prophylaxis in the postoperative period.
                                4. Recommend an appropriate VTE prophylaxis regimen for a postoperative patient.

                                Pharmacokinetics/Pharmacodynamics/Pharmacogenomics PRN and Global Health PRN Focus Session -- Precision Medicine in Diverse Populations: Global Considerations for Pharmacogenomics
                                October 28, 2019 1:45 PM

                                Activity No. 0217-0000-19-191-L01-P; 1.50 contact hours.
                                Knowledge Based Activity

                                • Moderator: Jacob T. Brown, Pharm.D.
                                  Assistant Professor, Department of Pharmacy Practice and Pharmaceutical Sciences, University of Minnesota, Minneapolis, Minnesota

                                Pharmacogenomic Differences and Identification of Novel Variants in Different Ethnic Populations
                                • Speaker: Erica L. Woodahl, Ph.D.
                                  Associate Professor, Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana
                                Learning Objectives
                                1. Review recent evidence for pharmacogenomic differences in different racial/ethnic populations.
                                2. Provide an update on observed variation with disparate allele frequencies between racial/ethnic groups.
                                3. Explain common challenges of implementing pharmacogenomics in different racial/ethnic populations.

                                Minimizing Racial Disparities in Pharmacogenomics Research and Practice
                                • Speaker: Minoli A. Perera, Pharm.D., Ph.D.
                                  Associate Professor of Pharmacology, Northwestern University, Chicago, Illinois
                                Learning Objectives
                                1. Review primary examples of racial disparities in pharmacogenomics.
                                2. Identify common challenges to pharmacogenomics research in racial/ethnic populations.
                                3. Describe strategies to overcome challenges in implementation in diverse patient populations.

                                International Strategies for Implementation of Pharmacogenomics
                                • Speaker: Jason H. Karnes, Pharm.D., Ph.D., BCPS
                                  Assistant Professor, University of Arizona, Tucson, Arizona
                                Learning Objectives
                                1. Review international implementation strategies and projects in diverse patient populations.
                                2. Discuss global strategies for initiating pharmacogenomics in health systems with diverse patient populations and diverse health care systems.
                                3. Compare examples of successful implementation of pharmacogenomics within the United States to successful implementation outside the US.

                                Panel Discussion

                                Research Basics
                                October 28, 2019 1:45 PM

                                Activity No. 0217-0000-18-205-L04-P; 4.00 contact hours.
                                Application Based Activity

                                • Moderator: Jimmi Hatton Kolpek, Pharm.D., FCCP, FCCM, FNAP
                                  Professor of Pharmacy, College of Pharmacy, Department of Pharmacy Practice and Science, University of Kentucky, Lexington, Kentucky
                                • Speaker: Gary L. Cochran, Pharm.D., S.M.
                                  Associate Professor of Pharmacy Practice, University of Nebraska Medical Center, College of Pharmacy, Omaha, Nebraska
                                • Speaker: Sandra L. Kane-Gill, Pharm.D., M.Sc., FCCP, FCCM
                                  Professor of Pharmacy and Therapeutics, University of Pittsburgh, School of Pharmacy, Pittsburgh, Pennsylvania
                                • Speaker: Jacqueline McLaughlin, Ph.D., M.S.
                                  Assistant Professor, Educational Innovation and Research; Director, Office of Strategic Planning and Assessment, University of North Carolina Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
                                • Speaker: Jeremy Thomas, Pharm.D.
                                  Associate Professor, Department of Pharmacy, University of Arkansas for Medical Sciences, College of Pharmacy, Little Rock, Arkansas
                                Learning Objectives
                                1. Describe common study designs used in observational, educational, health-services and cross-sectional/survey projects.
                                2. Discuss the advantages and disadvantages of the various study designs.
                                3. Discuss the optimal approach and suggested study design for your defined research question.
                                4. Identify resources needed for your research question and ideas for securing support.
                                5. Identify resources for learning how to write grants and obtain funding support in your research area.
                                6. Define the next three steps to take in creating a research funding development plan of action for your idea.
                                BCACP Clinical Session -- Don't Sugar Coat It: Hot Topics in the Management of Type 1 and Type 2 Diabetes Mellitus
                                October 28, 2019 2:00 PM

                                Activity No. 0217-9999-19-164-L01-P; 2.00 contact hours.
                                Application Based Activity

                                  Learning Objectives
                                  1. Differentiate between the 2015 and 2018 ADA and EASD consensus guidelines for treatment strategies.
                                  2. Critically evaluate the published literature regarding cardiovascular outcomes of medications for type 2 diabetes mellitus.
                                  3. Critically evaludate the published literature regarding renal outcomes of medications for type 2 diabetes mellitus.
                                  4. Interpret the potential use of non-insulin therapy for type 1 diabetes mellitus.
                                  5. Design a treatment regimen to optimize outcomes for patients with type 1 or type 2 diabetes mellitus.

                                  Introduction

                                  Treating Diabetes based on Cardiovascular Outcomes
                                  • Speaker: Jennifer N. Clements, Pharm.D., FCCP, BCPS, CDE, BCACP
                                    Clinical Pharmacist in Diabetes Transition, Spartanburg Regional Healthcare System, Spartanburg, South Carolina

                                  Treating Diabetes Based on Renal Outcomes
                                  • Speaker: Katie E. Cardone, FCCP, FNKF, FASN, BCACP
                                    Associate Professor, Albany College of Pharmacy and Health Sciences, Albany, New York

                                  Strategies with Non-Insulin Therapy for Type 1 Diabetes
                                  • Speaker: Benjamin N. Gross, Pharm.D., BCPS, BCACP, CDE, BC-ADM
                                    Associate Professor, Lipscomb University College of Pharmacy and Health Sciences, Nashville, Tennessee

                                  Panel Discussion

                                  Wrap-Up and Conclusions

                                  GI/Liver/Nutrition PRN and Ambulatory Care PRN Focus Session -- Challenges in Transitions of Care for Patients with Gastrointestinal, Liver, and Parenteral Nutrition-Dependent Diseases
                                  October 28, 2019 3:30 PM

                                  Activity No. 0217-0000-19-195-L05-P; 1.50 contact hours.
                                  Knowledge Based Activity

                                    Innovative Management Practices in the Treatment of Hepatitis C
                                    • Speaker: Rima A. Mohammad, Pharm.D., FCCP, BCPS
                                      Clinical Associate Professor of Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan
                                    Learning Objectives
                                    1. Identify medication management challenges with hepatitis C therapy continuation upon hospital admission/discharge.
                                    2. Analyze barriers of therapy continuation, adherence, and maintaining patient safety at transitions of care.
                                    3. Demonstrate innovative solutions in ambulatory clinics resulting, in improved patient-related outcomes.

                                    Overcoming Challenges in IBD Medication Management at Transitions of Care
                                    • Speaker: Bryan L. Love, PharmD, MPH
                                      Associate Professor, University of South Carolina College of Pharmacy, Columbia, South Carolina
                                    Learning Objectives
                                    1. Identify medication management challenges with IBD therapy continuation upon hospital admission/discharge..
                                    2. Analyze barriers of therapy continuation (e.g. biologics, biosimilars, dosage formulation changes, formulary challenges, coverage/reimbursement, etc.) during transitions of care.
                                    3. Demonstrate innovative solutions to these challenges applied in pharmacy practice, resulting in improved patient-related outcomes.

                                    Ensuring Safety at Transitions of Care for Parenteral Nutrition Dependent Patients
                                    • Speaker: Vanessa J. Kumpf, Pharm.D., BCNSP
                                      Clinical Specialist, Nutrition Support, Vanderbilt University Medical Center, Nashville, Tennessee
                                    Learning Objectives
                                    1. Identify medication management challenges in the parenteral nutrition process upon hospital admission/discharge.
                                    2. Analyze barriers of therapy continuation (e.g. institutional differences in parenteral nutrition practice, processes, and systems) during transitions of care.
                                    3. Demonstrate innovative solutions to these challenges applied in pharmacy practice, resulting in improved patient-related outcomes with a focus on safety (e.g. lack of PN order standardization leading to misinterpretation, PN order transcription errors, PN ordering/compounding software differences, etc.).

                                    Education and Training PRN Focus Session -- Tips and Tricks for Creating Opportunities for Educational Research Within Your Practice
                                    October 28, 2019 3:30 PM

                                    Activity No. 0217-0000-19-193-L04-P; 1.50 contact hours.
                                    Knowledge Based Activity

                                    • Moderator: Erica F. Crannage, Pharm.D., BCPS, BCACP
                                      Associate Professor, St. Louis College of Pharmacy; Clinical Pharmacist, Mercy Clinic-Family Medicine

                                    Principles, Nuances, and Challenges of Implementing SoTL in Experiential/practice Settings
                                    • Speaker: Elias B. Chahine, Pharm.D., FCCP, FFSHP, BCPS, BCIDP
                                      Professor of Pharmacy Practice, Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, Florida
                                    Learning Objectives
                                    1. Describe basic principles of designing and conducting educational research in experiential settings.
                                    2. Compare and contrast pedagogical vs clinical research.
                                    3. Employ strategies to implement educational research in the experiential setting.
                                    4. Identify common challenges encountered when conducting educational research.
                                    Describe basic principles of designing and conducting educational research in experiential settings

                                    Strategies to Mentor and Engage New Practitioners in Scholarship of Teaching & Learning
                                    • Speaker: Theresa Prosser, Pharm.D., FCCP, BCPS
                                      Professor, St Louis College of Pharmacy, St. Louis, Missouri
                                    • Speaker: Erin Hennessey, Pharm.D., BCPS
                                      Associate Professor of Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, Missouri
                                    Learning Objectives
                                    1. Describe strategies to mentor and engage pharmacy residents/fellows and new practitioners in SoTL.
                                    2. Summarize methods to implement SoTL when resources are limited.

                                    Clinical Administration PRN Focus Session -- The Planning and Implementation Process for Expanding Clinical Pharmacy Services
                                    October 28, 2019 3:30 PM

                                    Activity No. 0217-0000-19-192-L04-P; 1.50 contact hours.
                                    Application Based Activity

                                    • Moderator: Cynthia A. Brasher, Pharm.D., M.S., BCPS
                                      Pharmacy Operations Manager, Mission Hospital, Asheville, North Carolina

                                    Expansion of Pharmacy Services in an Acute Care Setting
                                    • Speaker: Richard J. Artymowicz, Pharm.D., MBA, FCCP, BCPS
                                      Director of Pharmacy Services and Administrative Director of Sleep and Wound Care Services, Cape Regional Medical Center, Cape May Court House, New Jersey
                                    Learning Objectives
                                    1. Identify clinical targets for pharmacy services expansion.
                                    2. Justify financially new FTEs for pharmacy service expansion.
                                    3. Describe the process necessary to align pharmacy service outcomes with organizational priority and/or regulatory requirements.
                                    4. Analyze an example of implementation of new pharmacy services.

                                    Expansion of Pharmacy Services in an Ambulatory Care Setting
                                    • Speaker: Amanda Brummel, Pharm.D.
                                      Vice President, Clinical Ambulatory Pharmacy Services Fairview Pharmacy Services, Minneapolis, Minnesota
                                    Learning Objectives
                                    1. Identify clinical targets for pharmacy services expansion.
                                    2. Justify new FTEs for pharmacy services.
                                    3. Describe the process to align pharmacy service outcomes with organizational priorities and/or regulatory requirements.
                                    4. Analyze and examples of implementation of new pharmacy services.

                                    Expansion of Pharmacy Services in Specialty Setting
                                    • Speaker: Sheila R. Botts, Pharm.D., FCCP, BCPP
                                      Regional Administrator Clinical Pharmacy Services, Kaiser Permanente, Colorado Region; Clinical Associate Professor, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado
                                    Learning Objectives
                                    1. Identify clinical targets for pharmacy services expansion.
                                    2. Justify new FTEs for pharmacy services expansion.
                                    3. Describe the process to align pharmacy service outcomes with organizational priorities and/or regulatory requirements.
                                    4. Analyze and examples of implementation of new pharmacy services.

                                    BCGP Clinical Session -- Self-Care Considerations in Older Adults: Integrating Complementary and Alternative Medicine
                                    October 28, 2019 4:15 PM

                                    Activity No. 0204-9999-19-290-L04-P; 1.00 contact hour.
                                    Application Based Activity

                                    • Speaker: Emily M. Ambizas, Pharm.D., B.S.Pharm., M.P.H., BCGP
                                      Associate Clinical Professor, St. John's University, New York City, New York
                                    Learning Objectives
                                    1. Identify common reasons for complementary and alternative medicine (CAM) use in the older adult.
                                    2. Evaluate evidence in the literature for the safety and efficacy of CAM use by the older adult.
                                    3. Develop recommendations for the appropriate use of CAM by the older adult.
                                    Clinical Reasoning Series in Pharmacotherapy - It’s All in the Head: Updates in Neuropsychiatric Pharmacotherapy in the Big and Small Part 1 (available for BCPS and BCPPS recertification credit)
                                    October 29, 2019 8:30 AM

                                    Activity No. 0217-0000-19-233-L01-P; 3.00 contact hours.
                                    Application Based Activity

                                    • Moderator: Robert Helmer, Pharm.D.

                                    Learning Objectives
                                    Identify adult and pediatric patients at risk for complications from substance abuse
                                    Determine the best therapeutic option(s) in managing acute and chronic alcohol or opioid abuse in adult, adolescent, and peripartum patients
                                    Apply clinical evidence to the management of neonatal abstinence syndrome

                                    Substance Abuse in Adult Patients
                                    • Speaker: Cherry W. Jackson, Pharm.D., FASHP, FCCP, BCPP
                                      Clinical Professor of Psychiatry and Behavioral Neurobiology, Auburn University Harrison School of Pharmacy, Auburn, Alabama

                                    Break

                                    Substance Abuse in Pediatric Patients
                                    • Speaker: Melissa C. Palmer, Pharm.D., BCPS, BCPP
                                      Clinical Assistant Professor, University of Missouri-Kansas (UMKC) City School of Pharmacy, Kansas City, Missouri

                                    ACCP Academy Mentor Meeting: How to be a Four Star Mentor
                                    October 29, 2019 9:00 AM

                                    Activity No. 0217-0000-19-222-L04-P; 1.00 contact hour.
                                    Knowledge Based Activity

                                    • Speaker: Robert E. Smith, Pharm.D.
                                      Professor Emeritus, Harrison School of Pharmacy, Auburn University, Auburn, Alabama
                                    Learning Objectives
                                    1. Define the concept of mentoring and mentoring partners.
                                    2. List what might be expected from a mentoring relationship.
                                    3. Construct a mentoring program for a less experienced individual in his or her organization.
                                    4. Construct his or her current and potential future career track.
                                    Healthcare in Rural and Medically Underserved Areas: Applications for Pharmacists
                                    October 29, 2019 10:15 AM

                                    Activity No. 0217-0000-19-166-L04-P; 1.50 contact hours.
                                    Application Based Activity

                                    • Moderator: Bryan J. Zobeck, Pharm.D., BCPS
                                      Clinical Pharmacist/Assistant Professor, University of Illinois Chicago College of Pharmacy at Rockford, Rockford, Illinois

                                    Improving Access to Care in Medically Underserved Communities
                                    • Speaker: Sharon E. Connor, Pharm.D.
                                      Associate Professor, University of Pittsburgh, Pittsburgh, Pennsylvania
                                    Learning Objectives
                                    1. Define rural and medically underserved areas and populations.
                                    2. Identify barriers to quality care in rural and medically underserved communities.
                                    3. Describe strategies to improve access to health care services in rural and underserved communities.
                                    4. Discuss solutions to improve patient health outcomes and population health for vulnerable populations.

                                    Implementation of Comprehensive Medication Management Services in Rural and Medically Underserved Communities
                                    • Speaker: Emily Kosirog, Pharm.D., BCACP
                                      Director of Clinical Pharmacy, Clinical Pharmacist, Salud Family Health Centers; Assistant Professor of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy, Aurora, Colorado
                                    Learning Objectives
                                    1. Compare pharmacy practice models in rural and medically underserved communities.
                                    2. List strategies and resources to develop comprehensive medication management services in rural and medically underserved communities.
                                    3. Perform a mind map for establishing or expanding a comprehensive medication management service in a medically underserved community.

                                    Question and Answer

                                    Thinning the Evidence: Practical Updates for Antiplatelet and Anticoagulant Therapy
                                    October 29, 2019 10:15 AM

                                    Activity No. 0217-0000-19-168-L01-P; 1.50 contact hours.
                                    Application Based Activity

                                    • Moderator: Dustin D. Spencer, Pharm.D., MBA, BCPS
                                      Clinical Director, Cardiopulmonary Diseases, Innovative Delivery Solutions, Cardinal Health, Houston, Texas

                                    Antiplatelet Therapy for Acute Coronary Syndromes: Refining Optimal Use from Practical Experience
                                    • Speaker: Joel C. Marrs, Pharm.D., MPH, BCACP, BCCP, BCPS, CHC, CLS
                                      Associate Professor, University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy & Pharmaceutical Sciences, Aurora, Colorado
                                    Learning Objectives
                                    1. Discuss the impact of opiates on delayed absorption of oral antiplatelet agents and recommend necessary treatment modifications to maximize antiplatelet effect.
                                    2. Describe the current place in therapy for cangrelor by reviewing clinical trial data and accumulating post-marketing experience.
                                    3. Examine evidence for switching oral P2Y12 receptor inhibitor therapy after initial treatment and describe the most appropriate method to switch therapy for a given clinical scenario.
                                    4. Formulate patient-specific antiplatelet treatment recommendations including agent choice and optimal duration considering indication, risk for thrombosis and bleeding, and other comorbidities.

                                    Directing the Course: Update on Oral Anticoagulation Post-ACS
                                    • Speaker: Shannon W. Finks, Pharm.D., FCCP, BCPS, BCCP, AHSCP-CHC
                                      Professor of Clinical Pharmacy University of Tennessee College of Pharmacy Memphis, Tennessee
                                    Learning Objectives
                                    1. Evaluate current evidence to tailor anticoagulation post-acute coronary syndrome for patients requiring triple-therapy.
                                    2. Discuss the use of low dose direct oral anticoagulants (DOACs) post-acute coronary syndrome.
                                    3. Review the recent data on bleeding rates with the combination use of DOACs and dual antiplatelet therapy (DAPT).

                                    Experiential Education: Tips and Strategies for Effectively Utilizing Learners to Overcome Preceptor Challenges
                                    October 29, 2019 10:15 AM

                                    Activity No. 0217-0000-19-165-L04-P; 1.50 contact hours.
                                    Application Based Activity

                                    • Moderator: Gina Prescott, Pharm.D., BCPS
                                      Clinical Associate Professor, School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York

                                    Utilizing Your Learner More Effectively in a Layered Learning Model
                                    • Speaker: Mate M. Soric, Pharm.D., FCCP, BCPS
                                      Chair and Associate Professor, Department of Pharmacy Practice, Northeast Ohio Medical University College of Pharmacy; Clinical Pharmacy Specialist, Internal Medicine, University Hospitals Geauga Medical Center, Rootstown, Ohio
                                    Learning Objectives
                                    1. Identify appropriate learning experiences for learners to serve as pharmacist extenders in clinical and research practices.
                                    2. Recognize clinical outcomes that can be achieved with learners through the layered learning model.
                                    3. Examine challenges and future opportunities when utilizing learners in the layered learning model.

                                    Block to the Future: Leveraging Longitudinal, Block Rotations to Meet Hospital and Learner Needs
                                    • Speaker: Aaron P. Hartmann, Pharm.D., BCPS
                                      Clinical Pharmacy Specialist, Barnes-Jewish Hospital, St. Louis, Missouri
                                    Learning Objectives
                                    1. Describe a longitudinal, block schedule at an academic medical center that effectively achieves departmental and learner goals.
                                    2. Identify key elements to successfully implementing and sustaining longitudinal, block rotations.
                                    3. Recognize challenges with implementing block scheduling.

                                    Challenging Situations: How to Overcome Challenges with Precepting Different Learners
                                    • Speaker: Brent N. Reed, Pharm.D., FAHA, BCPS-AQ Cardiology
                                      Associate Professor, University of Maryland School of Pharmacy; Clinical Pharmacy Specialist, University of Maryland Medical Center, Baltimore, Maryland
                                    Learning Objectives
                                    1. Discuss concerns for working with learners who have academic and physical challenges.
                                    2. Develop plans for working with learners who lack professional communication skills.
                                    3. Examine solutions for working with learners with academic and physical disabilities.

                                    Late Breaking Literature and Recent Developments in Clinical Pharmacy Practice
                                    October 29, 2019 10:15 AM

                                    Activity No. 0217-0000-19-167-L01-P; 1.50 contact hours.
                                    Knowledge Based Activity

                                    • Moderator: Drayton A. Hammond, Pharm.D., MBA, BCPS, BCCCP
                                      Clinical Pharmacy Specialist, Medical and Cardiac Intensive Care, Rush University Medical Center, Chicago, Illinois
                                    Learning Objectives
                                    1. Identify new and emerging clinical data and/or patient care trends that affect current/future pharmacotherapy and/or health care outcomes.
                                    2. Describe limitations and/or controversies associated with these late-breaking data.
                                    3. Discuss the implications of late-breaking data and/ emerging patient care trends on current clinical practice.

                                    Critical Care
                                    • Speaker: Melissa Chudow, Pharm.D., BCCCP
                                      Assistant Professor, University of South Florida School of Pharmacy, Tampa, Florida

                                    Oncology
                                    • Speaker: Sarah Maryon Hayes, Pharm.D., BCOP
                                      Oncology Clinical Specialist, North Memorial Health Care, Robbinsdale, Minnesota

                                    Transplantation
                                    • Speaker: Alicia Beth Lichvar, Pharm.D., MS
                                      Clinical Assistant Professor, University of Illinois at Chicago College of Pharmacy, Chicago, Illinois

                                    Infectious Diseases
                                    • Speaker: Erin K. McCreary, Pharm.D., BCPS, BCIDP
                                      Infectious Diseases Clinical Pharmacist, University of Pittsburgh Medical Center, Pittsburgh, PA

                                    Neurology
                                    • Speaker: Meghan Caylor, Pharm.D.
                                      Neurointensive Care Clinical Pharmacy Specialist, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

                                    Mental Health/Psychiatry
                                    • Speaker: Bennett J. Doughty, Pharm.D., BCPS, BCPP
                                      Assistant Professor, Binghamton University, State University of New York, Binghamton, New York

                                    Pediatrics
                                    • Speaker: Nicholas M. Fusco, Pharm.D., BCPS
                                      Clinical Associate Professor, University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York

                                    Question and Answer

                                    PSAP Live: Optimizing Treatment with Antidepressants and Antipsychotics (encore)
                                    October 29, 2019 10:15 AM

                                    Activity No. 0217-0000-19-190-L01-P; 1.50 contact hours.
                                    Application Based Activity

                                      Getting Things Done In Organizations
                                      October 29, 2019 10:15 AM

                                      Activity No. 0217-000-17-188-L04-P; 2.00 contact hours.
                                      Application Based Activity

                                      • Speaker: Robert E. Smith, Pharm.D.
                                        Professor Emeritus, Harrison School of Pharmacy, Auburn University, Auburn, Alabama
                                      Learning Objectives
                                      1. Review personal development principles.
                                      2. Discuss the elements of successful teams.
                                      3. Relate the importance of controlling ego.
                                      4. Apply the learned concepts to roles within ACCP and back home.
                                      5. Conduct a warm-up team building exercise.
                                      Clinical Reasoning Series in Pharmacotherapy - It’s All in the Head: Updates in Neuropsychiatric Pharmacotherapy in the Big and Small Part 2 (available for BCPS and BCPPS recertification credit)
                                      October 29, 2019 1:00 PM

                                      Activity No. 0217-0000-19-234-L01-P; 3.00 contact hours.
                                      Application Based Activity

                                      • Moderator: Robert Helmer, Pharm.D.

                                      Learning Objectives
                                      Discuss emerging therapeutic options in the management of migraine headaches in adults
                                      Determine the best therapeutic options(s) in managing an adult or pediatric patient with acute or chronic headache
                                      Apply clinical data to individual patient care and formulary decisions regarding drugs used for headache in adult and pediatric patients

                                      Headache in Adult Patients
                                      • Speaker: Kimberly B. Tallian, Pharm.D., FCCP, BCPP
                                        Advanced Practice Pharmacist - Psychiatry, Scripps Mercy Hospital, San Diego

                                      Break

                                      Headache in Pediatric Patients
                                      • Speaker: Kristine Parbuoni, Pharm.D., BCPPS
                                        Associate Professor, University of Maryland School of Pharmacy, Baltimore, Maryland

                                      Geriatrics PRN and GI/Liver/Nutrition PRN Focus Session -- Nutritional and Hepatic Concerns in the Older Adult: What's a Pharmacist To Do?
                                      October 29, 2019 1:15 PM

                                      Activity No. 0217-0000-19-183-L01-P; 1.50 contact hours.
                                      Knowledge Based Activity

                                      • Moderator: Kalin M. Clifford, Pharm.D., BCPS, BCGP

                                      Aging and Diseased Livers - Well, What am I Supposed to do Now?
                                      • Speaker: Jeffrey T. Sherer, Pharm.D., MPH, BCPS, BCGP
                                        Clinical Professor, University of Houston College of Pharmacy, Houston, Texas
                                      Learning Objectives
                                      1. Compare age-related changes to disease-related changes to the hepatic system and how it affects drug pharmacokinetics and pharmacodynamics.
                                      2. Examine the methodologies used to quantitate hepatic function.
                                      3. Using patient specific variables focusing on changes in hepatic function, provide appropriate therapeutic and monitoring recommendations.

                                      To Get the Feeding Tubes or Not: Understanding Malabsorption and Malnutrition in the Older Adult
                                      • Speaker: Anne M. Tucker, Pharm.D.
                                        Clinical Pharmacy Specialist – Critical Care/Nutrition Support, The University of Texas MD Anderson Cancer Center, Houston, Texas
                                      Learning Objectives
                                      1. Discuss malabsorption disorders (including when feeding tubes are indicated) and how this affects drug therapy in the older adult.
                                      2. Describe agents that can be used for appetite stimulation or treatment of malnutrition in all older adults across the age spectrum.
                                      3. Analyze a patient's medication list for potential absorption issues and administration considerations when feeding tubes are utilized.

                                      Interpreting Diagnostic Criteria and Treating Hepatitis C in Older Adults
                                      • Speaker: Michelle T. Martin, Pharm.D., FCCP, BCPS, BCACP
                                        Clinical Pharmacist and Clinical Associate Professor, University of Illinois at Chicago, Chicago, Illinois
                                      Learning Objectives
                                      1. Apply the Hepatitis C treatment and screening guidelines to older adults who are candidate for HCV therapy.
                                      2. Compare and contrast the efficacy and safety of direct acting antiviral medications to treat older adults with HCV.
                                      3. Given an older adult with multiple comorbid conditions, design an appropriate recommendations for those with hepatitis C.

                                      Global Health PRN and Infectious Diseases PRN Focus Session -- Updates in Global Infectious Diseases
                                      October 29, 2019 1:15 PM

                                      Activity No. 0217-0000-19-244-L01-P; 1.50 contact hours.
                                      Application Based Activity

                                      • Moderator: Susie J. Crowe, Pharm.D.
                                        Director of Experiential Education, Assistant Professor, Department of Pharmacy Practice, Bill Gatton College of Pharmacy, Johnson City, Tennessee

                                      Averting Vaccine Preventable Diseases in Underserved Patients
                                      • Speaker: Jeffery A. Goad, Pharm.D., MPH, BCPS
                                        Chapman University School of Pharmacy, Harry and Diane Rinker Health Science Campus, Irvine, California
                                      Learning Objectives
                                      1. Evaluate current trends in the resurgence of vaccine-preventable diseases around the world.
                                      2. Discuss ethnic and racial barriers to vaccination.
                                      2. Describe strategies to improve vaccination rates in underserved patients.

                                      Emerging Antimicrobial Resistance Globally
                                      • Speaker: Debra A. Goff, Pharm.D., FCCP
                                        Specialty Practice Pharmacist Infectious Diseases, The Ohio State University Wexner Medical Center; Clinical Associate Professor, OSU College of Pharmacy, Columbus, Ohio
                                      Learning Objectives
                                      1. Discuss limitations in identifying antimicrobial resistance globally.
                                      2. Describe strategies to reduce antimicrobial resistance and the development of superbugs on a global scale.
                                      3. Discuss treatment options for resistant infections taking into account the World Health Organization’s Model List of Essential Medicines.

                                      Implementing Teaching and Learning Strategies (Replacing Planning for Effective Teaching)
                                      October 29, 2019 1:15 PM

                                      Activity No. 0217-0000-18-068-L04-P; 4.00 contact hours.

                                      • Speaker: Daniel S. Longyhore, Pharm.D., M.S., BCACP
                                        System Director for Knowledge Management Geisinger, Enterprise Pharmacy, Wilkes Barre, Pennsylvania
                                      • Speaker: Kristi W. Kelley, Pharm.D., FCCP, BCPS, BCACP, BC-ADM, CDE
                                        Clinical Professor, Department of Pharmacy Practice, Auburn University Harrison School of Pharmacy; Clinical Pharmacist, Continuity Clinics, Brookwood Baptist Internal Medicine Residency Training Program, Birmingham, Alabama
                                      • Speaker: E. Kelly Hester, Pharm.D., FCCP, BCPS
                                        Associate Clinical Professor, Department of Pharmacy Practice, Auburn University Harrison School of Pharmacy, Auburn, Alabama
                                      Learning Objectives
                                      1. Optimize teaching methods that are directed toward the achievement of clearly-identified ability outcomes in large-scale and smaller-scale learning environments.
                                      2. Create learning environments in classrooms and practice sites that foster student learning, civility, and professional development
                                      Cardiology PRN Focus Session -- What’s New and Exciting in Cardiovascular Pharmacotherapy?
                                      October 29, 2019 1:15 PM

                                      Activity No. 0217-0000-19-182-L01-P; 1.50 contact hours.
                                      Knowledge Based Activity

                                      • Moderator: William L. Baker, Jr., Pharm.D., FCCP, FACC, FAHA
                                        Associate Professor of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, Connecticut

                                      How Should We Be Acutely Treating Ventricular Tachycardia in Patients with Structural Heart Disease?
                                      • Speaker: C. Michael White, Pharm.D., R.Ph.,FCCP
                                        Professor & Head, Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, Connecticut
                                      • Speaker: Kristen Bova Campbell, Pharm.D., BCPS
                                        Clinical Pharmacist - Electrophysiology, Duke University Hospital Residency Director, PGY2 Cardiology Residency,Duke University Hospital
                                      Learning Objectives
                                      1. Compare the effectiveness and safety of intensifying antiarrhythmic drug therapy versus catheter ablation for the treatment of ventricular tachycardia resistant to standard antiarrhythmic drugs.
                                      2. Devise a treatment strategy to optimally treat standard antiarrhythmic drug resistant ventricular tachycardia.

                                      Should mTOR inhibitors Have a Prominent Role in Immunosuppression Regimens After Heart Transplantation?
                                      • Speaker: Douglas L. Jennings, Pharm.D., FCCP, FAHA, FACC, BCPS
                                        Associate Professor, Department of Pharmacy Practice, Long Island University College of Pharmacy
                                      • Speaker: Edward Horn, Pharm.D., BCCCP
                                        Associate Professor, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania Clinical Pharmacy Specialist, Cardiac Transplantation and Mechanical Circulatory Support, UPMC HVI
                                      Learning Objectives
                                      1. Describe the current evidence regarding the role of de Novo mTOR inhibitor use and calcineurin inhibitor minimization/replacement as a routine part of immunosuppression regimens after heart transplantation.
                                      2. Examine the harms associated with the use of mTOR inhibitors as additions or replacements for calcineurin inhibitors after heart transplantation.

                                      Balancing Thrombosis and Bleeding Risk in Patients with a Durable Ventricular Assist Device.
                                      • Speaker: Ian B. Hollis, Pharm.D., BCPS-AQ Cardiology
                                        Clinical Pharmacy Specialist, Cardiac Surgery & Advanced Heart Failure, University of North Carolina Medical Center, Chapel Hill, NC
                                      Learning Objectives
                                      1. Explain recent technological advances in ventricular assist devices and their associated thrombotic & bleeding risk.
                                      2. Discuss the evidence supporting antithrombotic strategies with currently-available durable ventricular assist devices.
                                      3. Devise a treatment strategy to minimize the risk of bleeding in patients with a durable ventricular assist device.

                                      Question and Answer

                                      Diversity In Communication
                                      October 29, 2019 3:00 PM

                                      Activity No. 0217-0000-19-221-L04-P; 2.00 contact hours.
                                      Application Based Activity

                                      • Speaker: Robert S. Beardsley, Ph.D.
                                        Professor and Vice Chair for Administration, Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, Maryland
                                      • Speaker: Katherine P. Beardsley, Ph.D.

                                      Learning Objectives
                                      1. Identify the characteristics of an effective leader
                                      2.Identify solutions to enhance your leadership effectiveness when interacting with diverse individuals
                                      3.Describe strategies of how you can be more effective in your interactions with others, especially individuals from a different culture or of a different gender
                                      4.Apply the presented material to your professional and personal interactions with others
                                      Implementing Opioid Stewardship in Healthcare Facilities of Any Size
                                      October 29, 2019 3:00 PM

                                      Activity No. 0217-0000-19-169-L04-P; 1.50 contact hours.
                                      Application Based Activity

                                      • Moderator: Jennifer R. Bean, Pharm.D., BCPS, BCPP
                                        Clinical Pharmacy Specialist, VA-Tennessee Valley Healthcare System, Murfreesboro, Tennessee

                                      Experience of Implementing Opioid Stewardship Programs in National and Regional Health Systems
                                      • Speaker: Harminder Sikand, Pharm.D., FCCP, FASHP
                                        Clinical Director/Residency Director, Scripps Mercy Hospital. San Diego, California
                                      • Speaker: Chelsea Magee, Pharm.D., BCPS
                                        Lead Auditor Turnkey Pharmacy Solutions
                                      Learning Objectives
                                      1. Define and discuss the utilization of Opioid Stewardship Programs.
                                      2. Evaluate anticipated implementation barriers and strategies to overcome them.
                                      3. Provide an overview of the Opioid Stewardship Program in its entirety.

                                      Overcoming Challenges: Getting Results in Real World Opioid Stewardship Programs
                                      • Speaker: Chelsea Magee, Pharm.D., BCPS
                                        Lead Auditor Turnkey Pharmacy Solutions
                                      • Speaker: Harminder Sikand, Pharm.D., FCCP, FASHP
                                        Clinical Director/Residency Director, Scripps Mercy Hospital. San Diego, California
                                      Learning Objectives
                                      1. Discuss challenges that may be experienced in opioid stewardship programs, and methods of resolution.
                                      2. Describe the impact of the Opioid Stewardship Program.
                                      3. Design an individualized Opioid Stewardship Program to fit specific patient and institution needs.

                                      Central Nervous System PRN and Ambulatory Care PRN Focus Session -- Treatment Optimization of Psychiatric Disorders in Primary Care by Psychiatric and Ambulatory Care Pharmacists
                                      October 29, 2019 3:00 PM

                                      Activity No. 0217-0000-19-220-L01-P; 1.50 contact hours.
                                      Knowledge Based Activity

                                      • Moderator: Ashley M. McCormick, Pharm.D., BCPS
                                        Clinical Pharmacy Specialist, Honolulu, Hawaii

                                      Benefits of Incorporating Psychiatric Pharmacists within Primary Care Settings
                                      • Speaker: Caitlin McCarthy, Pharm.D.
                                        Clinical Assistant Professor, Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, New Brunswick, New Jersey
                                      Learning Objectives
                                      1. Discuss the advantages of incorporating mental health (MH) pharmacists in the primary care (PC) setting with a focus on earlier intervention, increased access, and consolidation of care.
                                      2. Compare and contrast MH in PC clinic models with respect to referral process, collaborative practice agreement structure, and continuum of care, by highlighting practices that have successfully implemented similar models.

                                      Managing the Interface of Mental Health and Physical Health: Mind and Body
                                      • Speaker: Morgan P. Stewart, PharmD
                                        University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado
                                      Learning Objectives
                                      1. Describe the clinical burden that various uncontrolled mental illnesses may pose on management of comorbid disease states such as diabetes, cardiovascular disease, chronic pain, and others.
                                      2. Identify clinical scenarios where adequate co-management of psychiatric and medical disease states may enhance safety and improve patient outcomes.

                                      An Introduction to Primary Care Psychiatry for the Non-psychiatric Pharmacist
                                      • Speaker: Lisa W. Goldstone, Pharm.D.
                                        USC School of Pharmacy, University of Southern California, Los Angeles, California
                                      Learning Objectives
                                      1. Recommend appropriate treatment and monitoring for low-complexity psychiatric conditions commonly encountered in the primary care setting.
                                      2. Identify when high-complexity psychiatric conditions can be treated in the primary care setting versus requiring referral to psychiatric specialty care.

                                      Pulmonary PRN Focus Session -- Updates in Pulmonary Hypertension Management Across the Continuum of Care
                                      October 29, 2019 3:00 PM

                                      Activity No. 0217-0000-19-196-L01-P; 1.50 contact hours.
                                      Application Based Activity

                                      • Moderator: Kristen T. Pogue, Pharm.D., BCPS-AQ Cardiology
                                        Clinical Pharmacist, Cardiology, University of Michigan Health System, Ann Arbor, Michigan

                                      Updates from the 6th World Symposium on Pulmonary Hypertension
                                      • Speaker: James C. Coons, Pharm.D., FCCP, BCCP
                                        Associate Professor, Department of Pharmacy and Therapeutics University of Pittsburgh School of Pharmacy Clinical Pharmacist, Cardiology UPMC Presbyterian Hospital
                                      Learning Objectives
                                      1. Describe the updated definition for the diagnosis of pulmonary arterial hypertension (PAH) and its implications on pharmacologic treatment.
                                      2. Select appropriate therapeutic goals and identify an appropriate timeline to evaluate a patient’s response to pharmacologic treatment of PAH.
                                      3. Evaluate patient-specific risk factors used to quantify disease severity and guide initial pharmacotherapy in patients diagnosed with PAH.

                                      Unique Challenges in the Management of Pulmonary Hypertension in the Ambulatory Setting
                                      • Speaker: Rebekah H. Anguiano, Pharm.D., BCPS, BCACP
                                        Clinical Assistant Professor, Pharmacy Practice; Clinical Pharmacist, Ambulatory Pharmacy Services, University of Illinois at Chicago, Chicago, Illinois
                                      Learning Objectives
                                      1. Identify barriers to treatment with PAH-targeted therapies in the ambulatory setting and available options to address and overcome these barriers.
                                      2. Evaluate patient-specific risk factors used to quantify disease severity and guide initial pharmacotherapy in patients diagnosed with PAH.
                                      3. Compose a pharmacotherapy regimen for a patient with PAH in the ambulatory setting.
                                      4. Identify strategies to address barriers associated with continuation of PAH-targeted therapies in patients transitioning between the ambulatory and acute care settings.

                                      Unique Challenges in the Management of Pulmonary Hypertension in the Critical Care Setting
                                      • Speaker: Amy L. Dzierba, Pharm.D., FCCM, BCPS, BCCCP
                                        Clinical Specialist, Critical Care Program Director, Critical Care Residency Department of Pharmacy, New York Presbyterian Hospital, New York, New York
                                      Learning Objectives
                                      1. Evaluate patient-specific risk factors used to quantify disease severity and guide initial pharmacotherapy in patients diagnosed with PAH.
                                      2. Identify strategies to address barriers associated with continuation of PAH-targeted therapies in patients transitioning between the ambulatory and acute care settings.
                                      3. Recognize barriers to initiation of PAH-targeted therapies in the acute care setting.

                                      Women's Health PRN Focus Session -- Pharmacotherapeutic Updates in Women’s Health: Focus on Human Papillomavirus, Female Sexual Dysfunction, and Menopause
                                      October 29, 2019 3:00 PM

                                      Activity No. 0217-0000-19-184-L01-P; 1.50 contact hours.
                                      Application Based Activity

                                      • Moderator: Lauren Leader, Pharm.D., BCPS
                                        Clinical Pharmacy Specialist - Obstetrics and Gynecology, Michigan Medicine, Ann Arbor, Michigan

                                      Public “Cervix” Message: Updates in Human Papillomavirus (HPV)
                                      • Speaker: Macary Weck Marciniak, Pharm.D., BCPS, FAPhA
                                        Clinical Associate Professor, University of North Carolina, Chapel Hill, North Carolina
                                      Learning Objectives
                                      1. Evaluate existing clinical recommendations data regarding long term efficacy regarding the use of the HPV vaccine.
                                      2. Identify implications of vaccine administration age expansion.
                                      3. Discuss emerging long term efficacy and safety data of the HPV vaccine.
                                      4. Identify the pharmacist’s role and potential barriers to increasing community administration of the vaccine.

                                      The Little Pink Pill: Updates in Female Sexual Dysfunction
                                      • Speaker: Sarah M. Westberg, Pharm.D., BCPS
                                        Co-Associate Dean of Clinical Affairs and Professor, University of Minnesota College of Pharmacy, Minneapolis, Minnesota
                                      Learning Objectives
                                      1. Analyze current US FDA approved therapies (Flibanserin) in the management of female sexual dysfunction (FSD).
                                      2. Discuss and novel uses of existing therapies utilized to treat FSD.
                                      3. Identify future medication therapies currently in development for management of FSD.

                                      Hot Flash News Flash: Updates in Menopause
                                      • Speaker: Veronica Vernon, Pharm.D., BCPS, BCACP
                                        Assistant Professor of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences, Indianapolis, Indiana
                                      Learning Objectives
                                      1. Interpret data regarding available pharmacotherapeutic options, for vasomotor and urogenital symptoms of menopause.
                                      2. Discuss emerging medication therapies, including efficacy and safety data, for the management of menopausal symptoms.
                                      3. Identify the pharmacist’s role in menopausal counseling.